

SEER Extent of Disease 1988
Codes and Coding Instructions

SEER

Cancer Statistics Branch
Surveillance Program
Division of Cancer Prevention and Control
National Cancer Institute

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

SEER EXTENT OF DISEASE -- 1988
CODES AND CODING INSTRUCTIONS

Prepared by:

Evelyn M. Shambaugh, M.A.
Lynn Gloeckler Ries, M.S.
John L. Young, Jr., Dr. PH
Mary A. Kruse
of the
Cancer Statistics Branch
Surveillance Program
National Cancer Institute

and

Charles E. Platz, M.D.
Robert F. Ryan, M.D.
Mildred A. Weiss, B.A.

Effective for cases diagnosed January 1, 1988 forward
Issued May, 1988

Revised January, 1989

We wish to express our appreciation to Robert Hutter, M.D., Liaison of the American Joint Committee to the SEER Program.

The original 13-digit Extent of Disease code was prepared for the SEER Program by the Extent of Disease Committee: Evelyn M. Shambaugh, M.A., Editor; Robert F. Ryan, M.D.; Lillian M. Axtell, M.A.; Howard B. Latourette, M.D.; Charles E. Platz, M.D.; Mildred A. Weiss, B.A.; and Robert L. Schmitz, M.D.

The original 2-digit Extent of Disease code was prepared for the End Results Group by the Extent of Disease Advisory Group: Paula Baylis, Editor; Robert F. Ryan, M.D.; Eugene A. Foster, M.D.; William I. Lourie, Jr., MPH; Mildred A. Weiss, B.A.; and Eugene J. Donlan.

Definitions of Abbreviations and Symbols

AJCC	American Joint Committee on Cancer	
cm	centimeter	
excl.	excluding, exclusive	
FIGO	Federation Internationale de Gynecologie et d'Obstetrique	
GE	Gastroesophageal	
GI	Gastrointestinal	
incl.	including, inclusive	
KUB	Kidneys, Ureters, Bladder	
L	left	
M-	Morphology code of the International Classification of Diseases for Oncology, Field Trial Edition (ICD-O, FT, 1988)	
mm	millimeter	
MSB	Main Stem Bronchus	
NOS	Not Otherwise Specified	
R	right	
SEER	Surveillance, Epidemiology and End Results	
T-	Topography code of the International Classification of Diseases for Oncology, Field Trial Edition (ICD-O, FT, 1988)	
TNM	Primary Tumor, Regional Lymph Nodes, Distant Metastasis	
<	less than	
>	greater than	
≤	less than or equal to	
≥	greater than or equal to	

TABLE OF CONTENTS

	Page
GENERAL INSTRUCTIONS...../.....	1
LIP (Vermilion or Labial Mucosa).....	12
BASE OF TONGUE, LINGUAL TONSIL.....	14
ANTERIOR 2/3's OF TONGUE, TIP, BORDER, AND NOS.....	16
MAJOR SALIVARY GLANDS.....	18
GUM (Gingiva), RETROMOLAR AREA.....	20
FLOOR OF MOUTH.....	22
CHEEK (Buccal) MUCOSA, VESTIBULE.....	24
HARD PALATE.....	26
SOFT PALATE, UVULA.....	28
OTHER MOUTH.....	30
OROPHARYNX.....	32
NASOPHARYNX.....	34
HYPOPHARYNX (Laryngopharynx).....	36
PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES.....	38
ESOPHAGUS.....	42
STOMACH.....	44
SMALL INTESTINE.....	46
COLON (incl. Flexures and Appendix)...	48
RECTOSIGMOID, RECTUM.....	50
ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM.....	52
LIVER, INTRAHEPATIC BILE DUCT(S).....	54
GALLBLADDER, OTHER BILIARY TRACT, NOS.....	56
EXTRAHEPATIC BILE DUCT(S).....	58
AMPULLA OF VATER.....	60
PANCREAS: HEAD, BODY, AND TAIL.....	62
PANCREAS, UNSPECIFIED.....	64
RETROPERITONEUM AND PERITONEAL SITES..	66
ILL-DEFINED DIGESTIVE AND PERITONEAL SITES.....	68
NASAL CAVITY, MIDDLE EAR.....	70
MAXILLARY SINUS.....	72
ACCESSORY (Paranasal) SINUSES (excl. Maxillary Sinuses).....	74
LARYNX.....	76
TRACHEA.....	78
LUNG, MAIN STEM BRONCHUS.....	80
PLEURA.....	82
HEART, MEDIASTINUM.....	84
ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS.....	86
BONE.....	88

TABLE OF CONTENTS

	Page
CONNECTIVE AND OTHER SOFT TISSUE.....	90
SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	92
MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM.....	94
MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM.....	96
BREAST.....	98
CERVIX UTERI.....	100
CORPUS UTERI, PLACENTA AND UTERUS, NOS.....	104
OVARY.....	106
FALLOPIAN TUBE AND BROAD LIGAMENT.....	108
VAGINA.....	110
VULVA (incl. Skin of Vulva) (excl. Mal- ignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	112
OTHER FEMALE GENITAL ORGANS.....	114
PROSTATE GLAND.....	116
TESTIS.....	118
PREPUCE, PENIS NOS, GLANS PENIS (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas).....	120
BODY OF PENIS, SCROTUM, AND OTHER MALE GENITAL ORGANS (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum).....	122
URINARY BLADDER.....	126
KIDNEY (Renal) PARENCHYMA.....	128
RENAL (Kidney) PELVIS, URETER, and URINARY SYSTEM, NOS.....	130
URETHRA AND PARAURETHRAL GLAND.....	132
EYE AND LACRIMAL GLAND.....	134
BRAIN AND CEREBRAL MENINGES.....	136
OTHER PARTS OF NERVOUS SYSTEM.....	138
THYROID GLAND.....	140
THYMUS AND OTHER ENDOCRINE GLANDS.....	142
KAPOSI'S SARCOMA OF ALL SITES.....	144
HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES (excl. Mycosis Fungoides and Sezary's Disease).....	146
HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE, AND MYELO- PROLIFERATIVE NEOPLASMS.....	148
UNKNOWN AND ILL-DEFINED SITES.....	150
INDEX.....	152

**General Instructions
for Using the SEER Extent of Disease --1988
Codes and Coding Instructions**

The Extent of Disease schemes consist of a ten-digit code to be submitted for each and every site. It will be identified by a '4' in Section IV, Field 12. This scheme replaces the 13-digit (SEER), the 2-digit (ERG), the non-specific, and the SEER 1983-87 four-digit schemes. It will apply to January 1, 1988 diagnoses and later. Do NOT replace schemes for cases diagnosed prior to January 1, 1988 with this scheme; cases diagnosed prior to 1988 will remain coded to whatever scheme was in operation at that time.

For ALL sites, extent of disease is based on a combined clinical and operative/pathological assessment. Gross observations at surgery are particularly important when all malignant tissue is not removed. In the event of a discrepancy between pathology and operative reports concerning excised tissue, priority is given to the pathology report.

Clinical information, such as description of skin involvement for breast cancer and size of the primary lesion and distant lymph nodes for any site, can change the stage. Thus, be sure to peruse the clinical information carefully to ensure accurate extent of disease. If the operative/pathology information disproves the clinical information, code the operative/pathology information.

Autopsy reports are used in coding Extent of Disease just as are pathology reports, applying the same rules for inclusion and exclusion.

Death Certificate only cases are coded as '9999999999' in the SEER Extent of Disease 1988 scheme.

Extent of Disease should be limited to all information available within two months after diagnosis for all cases.

Metastasis which is known to have developed after the original diagnosis was made should be excluded.

In coding size of tumor, code the size given prior to radiation therapy for surgical patients pretreated by radiation therapy. Do NOT code size after radiation therapy is given. |

General Instructions (cont'd)

Interpreting Ambiguous Terminology

- A. Tumor invasion "to", "into", "onto", or "encroaching upon" an organ or structure is to be interpreted as involvement whether the description is clinical or operative/pathological.
- B. "Probable", "suspected", "suspicious", "compatible with", or "consistent with" are to be interpreted as involvement by tumor.
- C. "Questionable", "possible", "suggests", or "equivocal" are **NOT** to be considered as evidence of involvement by tumor.
- D. "Induration" is used to describe surrounding fibrous or connective tissue adjacent to the tumor and is to be interpreted as extension of the malignant growth.

General Instructions (cont'd)

Extent of Disease Fields

The fields of information required for extent of disease are Tumor Size, Extension, Lymph Nodes, and the Pathology Review of Lymph Nodes.

I. TUMOR SIZE

Record the exact size of the primary tumor for all sites except where stated to be 'not applicable'. Record in tenths of CENTIMETERS (._ cm). Code '999' is reserved for unknown size.

Always code the size of the tumor, not the size of the polyp, ulcer, or cyst.

Do NOT add pieces or chips together to create a whole; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if an excisional biopsy is performed, and residual tumor is found at time of resection of the primary, code the size of the excisional biopsy tumor.

The descriptions in code '998' take precedence over any mention of size. Code '998' is used only for the following sites:

- Esophagus (150.0-150.5, 150.8-150.9): Entire circumference
- Stomach (151.0-151.6, 151.8-151.9): Diffuse, widespread--3/4's or more, linitis plastica
- Colorectal (M-8220/8221 with /2 or /3): Familial/multiple polyposis
- Lung and main stem bronchus (162.2-162.5, 162.8-162.9): Diffuse, entire lobe or lung
- Breast (174.0-174.6, 174.8-174.9, 175.9): Diffuse, widespread--3/4's or more of breast, inflammatory carcinoma

For the following sites, size is not applicable:

- Hematopoietic neoplasms
- Hodgkin's and non-Hodgkin's lymphoma
- Immunoproliferative diseases
- Kaposi's sarcoma
- Mycosis fungoides of skin
- Myeloproliferative diseases
- Malignant melanoma of skin, vulva, penis, and scrotum
- Sezary's disease of skin
- Unknown and ill-defined primary sites (199.9, 195.0-195.5, 195.8, 169._ and 196._)

For melanoma of skin, vulva, penis, and scrotum, SEER requires information on thickness of tumor instead of size to be coded in this field.

For Kaposi's sarcoma, SEER requires information on HTLV-4 instead of size to be coded in this field.

For mycosis fungoides and Sezary's disease of skin, vulva, penis, and scrotum, SEER requires information on peripheral blood involvement instead of size to be coded in this field.

If size is not recorded, code as '999'.

For in situ lesions, code the size as stated.

General Instructions (cont'd)

Determining Descriptive Tumor Size

CENTIMETER EQUIVALENTS FOR DESCRIPTIVE TERMS

<u>Fruits</u>	<u>cm</u>	<u>Miscellaneous Food</u>	<u>cm</u>
Apple	7	Doughnut	9
Apricot	4	Egg	5
Cherry	2	Bantam	1
Date	4	Goose	7
Fig (dried)	4	Hen	3
Grape	2	Pigeon	3
Grapefruit	10	Robin	2
Kumquat	5	Lentil	<1
Lemon	8	Millet	<1
Olive	2		
Orange	9	<u>Money</u>	
Peach	6	Dime	1
Pear	9	Dollar (silver)	4
Plum	3	Dollar (half)	3
Tangerine	6	Nickel	2
		Quarter	2
<u>Nuts</u>		Penny	1
Almond	3		
Chestnut	4	<u>Other</u>	
Chestnut (horse)	4	Ball (golf)	4
Hazel	2	Ball (ping-pong)	3
Hickory	3	Ball (tennis)	6
Peanut	1	Baseball	7
Pecan	3	Eraser on pencil	<1
Walnut	3	Fist	9
		Marble	1
<u>Vegetables</u>		Match (head)	<1
Bean	1	Microscopic	<1
Bean (lima)	2		
Pea	<1		
Pea (split)	<1		

SIZES IN CENTIMETERS, MILLIMETERS, INCHES

10 millimeters (mm) = 1 centimeter (cm)

2.5 centimeters (cm) = 1 inch (in)

1 millimeter (mm) = 1/10 centimeter (cm)

1 centimeter (cm) = .394 inch (in)

General Instructions (cont'd)

II. EXTENSION

The description of the primary tumor growth within the organ of origin or its extension to neighboring organs, or its metastasis to distant sites is summarized in a two-digit code. It is a hierarchical code in which the most extensive disease is all that is coded. Thus, information about the extent of the tumor within the primary site is lost if the tumor extends to neighboring organs, and extension to neighboring organs is lost if there is distant metastasis. Code '99' is reserved for unknown extension.

A "localized, NOS" category is provided for those cases in which the only description is "localized with no further information." "NOS" codes should be used only after an exhaustive search for more specific information.

If a tumor is described as "confined to mucosa," determine if it is limited to the epithelium (in situ) or if it has penetrated the basement membrane to invade the lamina propria.

III. LYMPH NODES

Regional lymph nodes are listed for each site and then, as necessary, the regional (first station) lymph nodes are classified in terms of size, laterality, number of involved nodes, and distance of the lymph nodes from the primary site. It is a one-digit field, a hierarchical code, in which once distant lymph node involvement is observed, all mention of regional nodal involvement is lost.

Since in situ by definition means noninvasive, code lymph node involvement as '0'. If there is evidence of nodal involvement of a tumor described as in situ, it would indicate that an area of invasion was simply missed, and it is **NOT** an in situ lesion.

For solid tumors, the terms "fixed" or "matted" and "mass in the mediastinum, retroperitoneum, and/or mesentery" (with no specific information as to tissue involved) are considered involvement of lymph nodes. Any other terms, such as "palpable", "enlarged", "visible swelling", "shotty", or "lymphadenopathy" should be ignored; look for a statement of involvement, either clinical or pathological.

For lymphomas, any mention of lymph nodes is indicative of involvement.

When size of involved regional lymph nodes is required, code from pathology report. |

General Instructions (cont'd)

Regional lymph nodes are not palpable for inaccessible sites such as bladder, kidney, lung, liver, and ovary. The best description you will have concerning regional lymph nodes will be the surgeon's evaluation at the time of exploratory surgery or definitive surgery.

The terms "homolateral" and "ipsilateral" are used interchangeably. Any unidentified nodes included with the resected primary site specimen are to be considered as "Regional, NOS."

Codes are provided for "regional lymph node(s), NOS" and for "lymph nodes, NOS." "NOS" codes should be used only after an exhaustive search for more specific information.

General Instructions (cont'd)

IV. PATHOLOGY REVIEW OF REGIONAL LYMPH NODES

Number of REGIONAL lymph nodes: POSITIVE nodes (first two-characters) and nodes EXAMINED (second two-characters) for all sites except the hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, the brain, cerebral meninges, and other parts of the nervous system, and unknown or ill-defined primary sites which are coded 9999. (This is based on pathology information ONLY.)

NUMBER OF REGIONAL NODES

<u>POSITIVE</u>	<u>EXAMINED</u>
00 All nodes examined negative	00 No nodes examined
01 One positive lymph node	01 One node examined
02 Two positive lymph nodes	02 Two nodes examined
..	..
..	..
10 Ten positive lymph nodes	10 Ten nodes examined
11 Eleven positive lymph nodes	11 Eleven nodes examined
..	..
..	..
96 96+	..
97 Positive nodes but number of positive nodes not specified	97+
98 No nodes examined	98 Nodes examined, but number unknown
99 UNKNOWN if nodes are positive or negative; not applicable	99 UNKNOWN if nodes were examined; not applicable

UNKNOWN AND NOT APPLICABLE

UNKNOWN will only be used when there is no descriptive information or when there is insufficient information because of an inadequate workup. It is to be used only if more specific information cannot be found except for Death Certificate only cases which are always coded '9999999999'.

Size of the Primary Tumor	999 - Not stated; not applicable
Extension	99 - UNKNOWN; not applicable
Lymph Nodes	9 - UNKNOWN; not stated; not applicable
Pathology Review	9999 - UNKNOWN; not applicable

Code 9's to indicate that a field is not applicable. For example, "Lymph Nodes" is not an applicable field for brain tumors or leukemia.

General Instructions (cont'd)

DISEASES DISSEMINATED AT DIAGNOSIS

Hematopoietic and reticuloendothelial neoplasms such as leukemia, multiple myeloma, reticuloendotheliosis, and Letterer-Siwe's disease, as well as immunoproliferative and myeloproliferative neoplasms are considered disseminated disease at diagnosis. These conditions will always be coded as systemic disease under Extension, and 9's in the remaining fields.

HODGKIN'S DISEASE and NON-HODGKIN'S LYMPHOMA

All lymphomas, both nodal and extranodal, will be coded to the lymphoma scheme (histology codes (M-9590-9594, 9650-9698, 9702-9704) except for mycosis fungoides (M-9700) and Sezary's disease (M-9701) which have a separate scheme found under the skin site codes 173._.

KAPOSI'S SARCOMA

Kaposi's sarcoma (M-9140) also has a separate scheme found just preceding the lymphomas.

HEAD AND NECK SITES

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR HEAD/NECK SITES

Careful attention must be given to the use of the term "confined to mucosa" for head and neck sites.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria.

The mucosa lining the oral cavity consists of:

The EPITHELIAL LAYER which borders on the lumen and contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The head and neck sites do NOT have a MUSCULARIS MUCOSAE. Therefore, the lamina propria and the submucosa tend to merge, and the two terms are used interchangeably.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands. Only the GUM and HARD PALATE do NOT have a submucosa, but rather a mucoperiosteum.

The MUSCULARIS PROPRIA is muscle tissue which constitutes the wall of the organ. Only the GUM and HARD PALATE do NOT have a muscularis.

There is no SEROSA on any of the head and neck sites.

HEAD AND NECK SITES

PRIMARY SITE	MUCOSA		SUBMUCOSA	MUSCULARIS PROPRIA	SEROSEA
	Epithelium	Lamina Propria			
Lip (140._)	Yes	Yes	Yes	Yes	No
Tongue (141._)	Yes	Yes	Yes	Yes	No
Gum (143._)	Yes	Yes	No	No	No
Floor of Mouth (144._)	Yes	Yes	Yes	Yes	No
Buccal Mucosa (145.0-145.1)	Yes	Yes	Yes	Yes	No
Hard Palate (145.2)	Yes	Yes	No	No	No
Soft Palate (145.3-145.4)	Yes	Yes	Yes	Yes	No
Other Mouth (145.5, .8-.9)	Yes	Yes	Yes	Yes	No

For the above head and neck sites and for the pharynx and its subsites, if a tumor is described as "confined to mucosa," determine if it is limited to the epithelium (in situ) or if it has penetrated the basement membrane to invade the lamina propria.

LIP (Vermilion or Labial Mucosa)
 140.0-140.1, 140.3-140.6, 140.8-140.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to:
 - Lamina propria
 - Submucosa (superficial invasion)
 - Vermilion surface
 - Labial mucosa (inner lip)
 - Subcutaneous soft tissue of lip
 - Skin of lip
- 20 Musculature
- 30 Localized, NOS
- 50 Buccal mucosa (inner cheek)
 Opposite (both) lip(s);
 commissure
- 51 Gingiva
- 70 **Upper lip/commissure:**
 Maxilla
Lower lip/commissure:
 Mandible
- 75 Tongue
- 76 Nose for upper lip/commissure
 Skin of face/neck
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes labial mucosa (140.3-140.5) with buccal mucosa (145.0).

LIP (Vermilion or Labial Mucosa)
140.0-140.1, 140.3-140.6, 140.8-140.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Upper Lip:

Facial: Buccinator
Submandibular (submaxillary)
Parotid: Infra-auricular/pre-auricular

Lower Lip:

Facial: Mandibular
Submandibular (submaxillary)
Submental
Internal jugular (upper deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS

Commissure: All nodes listed above

Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

BASE OF TONGUE, LINGUAL TONSIL
141.0, 141.6

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
Lamina propria
Submucosa
- 20 Musculature, intrinsic or NOS
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Anterior 2/3's of tongue
Lower gingiva
Floor of mouth
- 53 Sublingual gland
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
Vallecula, incl. pharyngoepiglottic and glossoepiglottic folds
Epiglottis, lingual (pharyngeal) surface
Soft palate, inferior surface/NOS
- 70 Mandible
- 75 Musculature, extrinsic:
Hyoglossus
Genioglossus
Styloglossus
- 76 Skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes base of tongue (141.0) with oropharynx (146._).

BASE OF TONGUE, LINGUAL TONSIL
141.0, 141.6

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid

Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

ANTERIOR 2/3's of TONGUE, TIP, BORDER, AND NOS
 141.1-141.5, 141.8-141.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

EXTENSION

000 No mass; no tumor found
 001 Microscopic focus or foci only

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
 Lamina propria
 Submucosa
- 20 Musculature, intrinsic or NOS
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Base of tongue
 Gingiva, lower (incl. retromolar trigone)
 Floor of mouth
- 53 Sublingual gland
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
 Soft palate, inferior surface
- 70 Mandible
 Maxilla
- 75 Musculature, extrinsic:
 Hyoglossus
 Genioglossus
 Styloglossus
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

ANTERIOR 2/3's of TONGUE, TIP, BORDER, AND NOS
141.1-141.5, 141.8-141.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Sublingual

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

MAJOR SALIVARY GLANDS
142.0-142.2, 142.8-142.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU; noninvasive
- 10 Invasive tumor confined to gland of origin
- 30 Localized, NOS
- 40 Periglandular soft/connective tissue
Other major salivary gland (parotid, submaxillary, sublingual)
Periosteum of mandible
Skeletal muscle: Digastric, pterygoid, stylohyoid

Parotid gland only:
Skin overlying gland
External auditory meatus
Facial nerve
Pharyngeal mucosa
Skeletal muscle: Sternocleido-mastoid, masseter

Submandibular gland only:
Skeletal muscle: Mylohyoid, hyoglossus, styloglossus
- 50 **Parotid gland only:**
Skull; mastoid
Mandible
Nerves: Auricular, spinal accessory
Major blood vessel(s): Carotid artery, jugular vein

Submandibular gland only:
Mandible
Nerves: Facial, lingual
Major blood vessels: Facial artery or vein, maxillary artery
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Parotid gland only:

Intraparotid, infra-auricular,
preauricular

Submandibular gland only:

Submandibular (submaxillary)
Submental
Internal jugular (upper deep
cervical):
jugulodigastric

Parotid and Submandibular glands:

Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

Note: If laterality is not specified, assume nodes are ipsilateral.

GUM (Gingiva), RETROMOLAR AREA
 143.0-143.1, 143.8-143.9, 145.6

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to mucoperiosteum (stroma)
- 30 Localized, NOS
- 50 Buccal mucosa (inner cheek) |
 Labial mucosa (inner lip), lip
Upper gum only:
 Hard palate
 Soft palate
Lower gum/retromolar trigone only:
 Floor of mouth
 Tongue
- 55 Subcutaneous soft tissue of face
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
- 70 **Upper gum only:**
 Maxilla
Lower gum/retromolar trigone only:
 Mandible
- 73 Skull
- 74 **Upper gum only:**
 Nasal cavity
 Maxillary antrum (sinus)
- 76 Skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Facial: Mandibular
Submandibular (submaxillary)
Submental for lower gum
Retropharyngeal for upper gum
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not specified, assume nodes are ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

FLOOR OF MOUTH
 144.0-144.1, 144.8-144.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
 Lamina propria
 Submucosa
- 20 Musculature, extrinsic: Mylohyoid and hyoglossus
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Gingiva (alveolar ridge), lower Anterior 2/3's of tongue
 Base of tongue
- 53 Sublingual gland, incl. ducts
 Submandibular (submaxillary) glands, incl. ducts
- 55 Subcutaneous soft tissue
- 60 Epiglottis, pharyngeal (lingual) surface
 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
 Vallecula, incl. pharyngo-epiglottic and glosso-epiglottic folds
- 70 Mandible
- 76 Skin of undersurface of chin/neck
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Submental

Sublingual

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

CHEEK (Buccal) MUCOSA, VESTIBULE
145.0-145.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to:
Lamina propria
Submucosa
- 20 Musculature (buccinator)
- 30 Localized, NOS
- 50 Lip(s), incl. commissure
- 51 Gingiva
- 55 Subcutaneous soft tissue of cheek
- 60 Lateral pharyngeal wall (tonsillar pillars and fossae, tonsils)
- 70 Bone: Maxilla, mandible
- 73 Skull
- 75 Tongue
- 76 Skin of cheek (WITH or WITHOUT ulceration)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: ICD-7, T-145.0 for buccal mucosa includes the membrane lining of the cheeks but not of the lips. (AJCC includes labial mucosa with buccal mucosa.)

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Facial: Buccinator, mandibular
Submandibular (submaxillary)
Parotid: Preauricular, infra-auricular
Internal jugular (upper deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not specified, assume nodes are ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral positive nodes ≤6 cm or size not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

HARD PALATE
145.2

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to mucoperiosteum (stroma)
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Soft palate
Gingiva, upper
Buccal mucosa (inner cheek)
- 70 Palatine bone
Maxillary bone
- 74 Nasal cavity
Maxillary antrum (sinus)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid

Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

SOFT PALATE, UVULA
145.3-145.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor on one side confined to:
Lamina propria
Submucosa
- 20 Musculature invaded |
- 30 Localized, NOS
- 40 Tumor crosses midline
- 50 Hard palate |
Gum (gingiva), upper
Buccal mucosa (inner cheek)
- 60 Lateral pharyngeal wall |
(tonsillar pillars and fossae, tonsils)
- 70 Palatine bone (bone of hard palate)
Maxilla
Mandible
- 74 Nasopharynx
Nasal cavity
Maxillary antrum (sinus)
- 75 Tongue
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note 1: AJCC includes inferior surface of the soft palate (145.3) and uvula (145.4) with oropharynx (146._).

Note 2: Soft palate excludes nasopharyngeal (superior) surface of soft palate (147.3).

Note 3: Code 145.6, retromolar area, is included with gum (143._).

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Retropharyngeal
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not
specified, assume nodes are
ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

OTHER MOUTH
 145.5, 145.8-145.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive;
 intraepithelial

10 Invasive tumor confined to:
 Lamina propria
 Submucosa

20 Musculature

30 Localized, NOS

50 Adjacent oral cavity |

60 Extension to oropharynx:
 Lateral pharyngeal wall
 Vallecula
 Lingual surface of epiglottis
 Inferior surface of soft palate

70 Extension to adjacent |
 structures:
 Maxilla, mandible, skull
 Maxillary antrum; nasal cavity
 Tongue
 Skin of face/neck

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid

Cervical, NOS
Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

OROPHARYNX
146.0-146.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

Anatomic Limits of Oropharynx

ANTERIOR WALL consists of the lingual (anterior) surface of the epiglottis and the pharyngoepiglottic and glossoepiglottic folds which bound the vallecula (the hollow formed at the junction of the base of the tongue and the epiglottis).

LATERAL WALLS include the tonsillar pillars, the tonsillar fossae, and the palatine (faucial) tonsils. On each side, the anterior pillar (glossopalatine fold) extends from the base of the tongue to the soft palate lying in front of the tonsillar fossa.

POSTERIOR WALL extends from a level opposite the free borders of the soft palate to the tip of the epiglottis.

AJCC has added a new subsite, Superior Wall, to the site of OROPHARYNX, which includes the inferior surface of the soft palate and uvula. SEER codes soft palate and uvula to ICD-0, 145.3 and 145.4.

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
 - Anterior wall (incl. vallecula and lingual (anterior) surface of epiglottis)
 - One lateral wall
 - Posterior wall
- 20 Involvement of two or more subsites: Posterior, anterior or lateral wall(s)
- 30 Localized, NOS
- 40 Soft palate, inferior surface, incl. uvula, or soft palate, NOS
- 41 Pyriform sinus (incl. hypopharynx, NOS)
- 42 Soft palate, superior (nasopharyngeal) surface
Nasopharynx, NOS
- 50 Base of tongue
 - Laryngeal (posterior) surface of epiglottis, or larynx, NOS
 - Floor of mouth
 - Gum (gingiva)
 - Buccal mucosa (inner cheek)
- 55 Any of above WITH fixation
- 60 Prevertebral fascia or muscle
Soft tissue of neck
- 70 Bone
 - Extrinsic muscles of tongue: Mylohyoid, hyoglossus, styloglossus
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note 1: If laterality is not specified, assume nodes are ipsilateral.

Note 2: AJCC includes base of tongue (141.0) with oropharynx (146._).

Note 3: AJCC includes lingual (anterior) surface of epiglottis (146.4) with larynx (161._).

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

NASOPHARYNX

147.0-147.3, 147.8-147.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
Posterior superior wall (vault)
One lateral wall
Inferior wall (superior surface of soft palate)
- 20 Involvement of two or more subsites:
Posterior, inferior, or lateral wall(s)
Lateral wall extending into eustachian tube/middle ear
- 30 Localized, NOS
- 40 Soft palate, inferior surface
Oropharynx
- 50 Nasal cavity
- 52 Pterygopalatine fossa
- 55 Any of the above WITH fixation or tumor described **only** as FIXED
- 60 Bone, including skull
- 70 Brain, incl. cranial nerves
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Anatomic Limits of Nasopharynx

POSTERIOR SUPERIOR WALL extends from the choana, or the opening of the nasal cavities into the nasopharynx, posteriorly to a level opposite the soft palate. The pharyngeal tonsils (adenoids) are located in this part of the nasopharynx.

LATERAL WALLS extend from the base of the skull to the level of the soft palate and include Rosenmuller's fossa (pharyngeal recess).

INFERIOR ANTERIOR WALL consists of the superior surface of the soft palate.

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not
specified, assume nodes are
ipsilateral.

- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

HYPOPHARYNX (Laryngopharynx)
 148.0-148.3, 148.8-148.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

Anatomic Limits of Hypopharynx

POSTCRICOID AREA (pharyngoesophageal junction) extends from the level of the arytenoid cartilages and connecting folds to the inferior border of the cricoid cartilage.

PYRIFORM SINUS extends from the pharyngoepiglottic fold to the upper edge of the esophagus. It is bounded laterally by the thyroid cartilage and medially by the hypopharyngeal surface of the aryepiglottic fold and the arytenoid and cricoid cartilages.

POSTERIOR HYPOPHARYNGEAL WALL extends from the level of the tip of the epiglottis to the inferior margin of the cricoid cartilage and laterally to the posterior margins of the pyriform sinus.

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to one of the following subsites:
 Postcricoid area
 Pyriform sinus
 Posterior pharyngeal wall
- 20 Tumor involves adjacent subsite(s) (listed above) WITHOUT fixation
- 30 Localized, NOS
- 40 Oropharynx
- 50 Larynx
 Cervical (upper) esophagus
- 51 Any of the above WITH fixation of tumor or fixation, NOS
- 55 Fixation of hemilarynx or larynx
- 60 Prevertebral muscle(s)
 Soft tissue of neck, cartilage
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

HYPOPHARYNX (Laryngopharynx)
148.0-148.3, 148.8-148.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper and
lower deep cervical):
jugulodigastric
jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

Note: If laterality is not
specified, assume nodes are
ipsilateral.

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES
149.0-149.1, 149.8-149.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to site of origin
- 30 Localized, NOS
- 40 More than one region of pharynx involved (oropharynx, nasopharynx, hypopharynx)
- 50 Pharynx and oral cavity involved
- 55 Any of the above WITH fixation
- 60 Extension to adjacent structures
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

PHARYNX NOS AND OTHER ILL-DEFINED ORAL CAVITY SITES
149.0-149.1, 149.8-149.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submandibular (submaxillary)

Internal jugular (upper and
lower deep cervical):

jugulodigastric

jugulo-omohyoid

Retropharyngeal

Cervical, NOS

Regional lymph node(s), NOS

1 One positive ipsilateral node
≤3 cm in greatest diameter

2 One positive ipsilateral node
>3-6 cm in greatest diameter

3 Multiple positive ipsilateral
nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated

6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

DIGESTIVE SYSTEM SITES

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR THE DIGESTIVE SYSTEM

Careful attention must be given to the use of the term "confined to mucosa" for the esophagus, stomach, small intestine, colon and rectum.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria.

The mucosa of the digestive tract consists of:

The EPITHELIAL LAYER borders on the lumen. It contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The MUSCULARIS MUCOSAE is a thin layer of smooth muscle fibers. It is found in the wall of the digestive tract from the esophagus to the anal canal.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands.

The MUSCULARIS PROPRIA is a double layer of muscle tissue in most of the digestive tract; it constitutes the wall of the organ.

DIGESTIVE SYSTEM SITES

The SEROSA, the outermost layer covering most of the digestive tract, is a single layer of squamous epithelial cells, part of the visceral peritoneum. Just below the serosa (mesothelium) and sometimes considered part of the serosa, is a layer of connective tissue called the subserosa. The serosa and subserosa are present only in the peritonealized portions of the digestive tract. For the esophagus and in the rectum below the peritoneal reflection, there is no serosa. For the esophagus, the connective tissue of surrounding structures merges with the connective tissue of the esophagus and is called ADVENTITIA.

DIGESTIVE SYSTEM SITES

PRIMARY SITE	MUCOSA			SUB-MUCOSA	MUSCULARIS PROPRIA	SEROSA	
	Epithelium	Lamina Propria	Muscularis Mucosae				
Esophagus (150._)	Yes	B A S	Yes	Yes	Yes	Yes	No
Stomach (151._)	Yes	E M E	Yes	Yes	Yes	Yes	Yes
Sm. Intestine (152._)	Yes	N T	Yes	Yes	Yes	Yes	Yes
Colon (153._)	Yes	M E M	Yes	Yes	Yes	Yes	Yes
Rectosigmoid (154.0)	Yes	B R A	Yes	Yes	Yes	Yes	Yes
Rectum (154.1)	Yes	N E : :	Yes	Yes	Yes	Yes	No

ESOPHAGUS

150.0-150.5, 150.8-150.9

SIZE OF PRIMARY TUMOR/LENGTH OF INVOLVED ESOPHAGUS

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Entire circumference	
999	Not stated	

Anatomic Limits of Esophagus**CERVICAL ESOPHAGUS (150.0):** From the lower border of the cricoid cartilage to the thoracic inlet (suprasternal notch), about 18 cm from the incisors.**INTRATHORACIC ESOPHAGUS (150.1-.5):**
Upper thoracic portion (150.3):
From the thoracic inlet to the level of the tracheal bifurcation (18-24 cm)Mid-thoracic portion (150.4):
From the tracheal bifurcation midway to the gastroesophageal (GE) junction (24-32 cm). |Lower thoracic portion (150.5):
From midway between the tracheal bifurcation and the gastroesophageal junction to the GE junction, including the abdominal esophagus (150.2) between 32-40 cm.**EXTENSION**

00	IN SITU: Noninvasive; intraepithelial
	Invasive tumor confined to:
10	Mucosa, NOS (incl. intramucosal)
11	Lamina propria
12	Muscularis mucosae
16	Submucosa
20	Muscularis propria invaded
30	Localized, NOS
40	Adventitia and/or soft tissue invaded; esophagus is described as "FIXED"
60	Cervical esophagus: Major blood vessel(s): Carotid and subclavian arteries, jugular vein Thyroid gland
	Intrathoracic, upper or mid-portion, esophagus: Major blood vessel(s): Aorta, pulmonary artery/vein, vena cava, azygos vein Trachea, incl. carina Main stem bronchus
	Intrathoracic, lower portion (abdominal), esophagus: Major blood vessel(s): Aorta, gastric artery/vein, vena cava Diaphragm Stomach, cardia
65	Cervical esophagus: Hypopharynx Larynx Trachea, incl. carina Cervical vertebra(e)
	Intrathoracic esophagus: Lung via bronchus Pleura Mediastinal structure(s), NOS Rib(s); thoracic vertebra(e)

EXTENSION (cont'd)

- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: Ignore intraluminal extension to adjacent segment(s) of esophagus and code depth of invasion or extra-esophageal spread as indicated.

LYMPH NODES

0 No lymph node involvement

1 REGIONAL Lymph Nodes (incl. contralateral or bilateral)

Cervical only:

- Peri-/paraesophageal
- Superior mediastinal
- Internal jugular (upper deep cervical):
 - jugulodigastric
 - jugulo-omohyoid
- Cervical, NOS

Intrathoracic, upper or middle, only:

- Peri-/Paraesophageal
- Internal jugular (upper and lower deep cervical):
 - jugulodigastric
 - jugulo-omohyoid
- Cervical, NOS

Intratracheobronchial:

- peritracheal, carinal (bifurcation), hilar (pulmonary roots)
- Left gastric: Cardiac, lesser curvature, perigastric, NOS
- Posterior mediastinal

Intrathoracic, lower (abdominal), only:

- Peri-/Paraesophageal
- Left gastric: Cardiac, lesser curvature, perigastric, NOS
- Posterior mediastinal

Regional lymph node(s), NOS

DISTANT Lymph Nodes

6 Supraclavicular lymph nodes

7 Other than above

8 Lymph nodes, NOS

9 UNKNOWN; not stated

STOMACH

151.0-151.6, 151.8-151.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Diffuse; widespread; 3/4's or more: Linitis plastica	
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in head of polyp, stalk not invaded
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Extension to adjacent (connective) tissue:
Perigastric fat
Omentum, lesser, greater, NOS
Ligaments: Gastrocolic, gastrohepatic, gastrosplenic
Gastric artery
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 Spleen
Transverse colon (incl. flexures)
Liver
Diaphragm
Pancreas
Esophagus via serosa
Duodenum via serosa or NOS
Jejunum, ileum, small intestine, NOS

Note: Ignore intraluminal extension to esophagus and duodenum; code depth of invasion through stomach wall.

EXTENSION (cont'd)

LYMPH NODES

<p>70 Abdominal wall Retroperitoneum Kidney Adrenal gland</p> <p>80 FURTHER extension</p> <p>85 Metastasis</p> <p>99 UNKNOWN if extension or metastasis</p>	<p> 0 No lymph node involvement - - - - -</p> <p> REGIONAL Lymph Nodes</p> <p style="padding-left: 20px;">Inferior (R) gastric: Greater curvature Greater omental Gastroduodenal Gastrocolic Gastroepiploic, right or NOS Gastrohepatic Pyloric, incl. sub-/infrapyloric Pancreaticoduodenal</p> <p style="padding-left: 20px;">Splenic: Gastroepiploic, left Pancreaticocoliinal Peripancreatic Splenic hilar</p> <p style="padding-left: 20px;">Superior (L) gastric: Lesser curvature Lesser omentum Gastropancreatic, left Gastric, left Paracardial; cardial Cardioesophageal</p> <p style="padding-left: 20px;">Perigastric, NOS Nodule(s) in perigastric fat</p> <p>1 Perigastric nodes ≤3 cm from the primary tumor</p> <p>2 Perigastric nodes >3 cm from the primary tumor</p> <p>4 Celiac Hepatic (excl. gastrohepatic)</p> <p>5 Regional lymph node(s), NOS - - - - -</p> <p>DISTANT Lymph Nodes</p> <p>7 Other than above .</p> <p>- - - - -</p> <p>8 Lymph nodes, NOS</p> <p>9 UNKNOWN; not stated</p>
---	---

SMALL INTESTINE
152.0-152.3, 152.8-152.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in head of polyp, stalk not invaded
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Adjacent connective tissue
Mesentery, incl. mesenteric fat
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 **Duodenum:**
Extrahepatic bile ducts, incl. ampulla of Vater
Pancreas
Pancreatic duct

Note: Ignore intraluminal extension to adjacent segment(s) of small intestine and code depth of invasion or spread outside the small intestine as indicated.

EXTENSION (cont'd)

LYMPH NODES

<p>65 Duodenum: Transverse colon, hepatic flexure Greater omentum; omentum, NOS Right or quadrate lobe of liver; liver, NOS Right kidney or ureter; kidney, NOS Major blood vessel(s): Aorta, superior mesenteric artery or vein, vena cava, portal vein, renal vein, gastroduodenal artery</p> <p>Jejunum and Ileum: Large intestine, incl. appendix</p>	<p>0 No lymph node involvement ----- 1 REGIONAL Lymph Nodes</p> <p>Duodenum: Hepatic: Pancreaticoduodenal Infrapyloric Gastroduodenal</p> <p>Jejunum and Ileum: Posterior cecal (terminal ileum) Ileocolic (terminal ileum) Superior mesenteric; mesenteric, NOS</p> <p>Regional lymph node(s), NOS -----</p>
<p>66 Duodenum: Stomach</p>	<p>DISTANT Lymph Nodes</p>
<p>67 All small intestine sites: Abdominal wall Retroperitoneum</p>	<p>7 Other than above -----</p>
<p>68 All small intestine sites: Small intestine via serosa</p>	<p>8 Lymph Nodes, NOS</p> <p>9 UNKNOWN; not stated</p>
<p>70 Jejunum and Ileum: Bladder Uterus Ovary; fallopian tube</p>	
<p>80 FURTHER extension</p>	
<p>85 Metastasis</p>	
<p>99 UNKNOWN if extension or metastasis</p>	

COLON (incl. Flexures and Appendix)
153.0-153.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

998 Familial/multiple polyposis
(M-8220/8221)
999 Not stated

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in head of polyp, stalk not invaded
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS/confined to colon, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat, invaded
- 45 Extension to adjacent (connective) tissue:
Mesentery (incl. mesenteric fat, mesocolon)--all colon sites
Retroperitoneal fat--ascending and descending colon
Greater omentum; gastrocolic ligament--transverse colon
Pericolic fat--all colon sites
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)
- 60 Greater omentum--cecum, appendix, ascending, descending and sigmoid colon
Spleen--descending colon
Pelvic wall--descending colon/sigmoid
Liver, right lobe--ascending colon

Note: Ignore intraluminal extension to adjacent segment(s) of colon; code depth of invasion or extracolonic spread as indicated.

EXTENSION (cont'd)

- Transverse colon and flexures:**
 - Stomach
 - Spleen; liver
 - Pancreas
 - Gallbladder/bile ducts
 - Kidney
- All colon sites:**
 - Small intestine
- 65 **All colon sites:**
 - Abdominal wall
 - Retroperitoneum (excl. fat)
- 66 **Ureter/kidney**
 - Right--ascending colon
 - Left--descending colon
- 70 **Cecum, appendix, ascending, descending, and sigmoid colon:**
 - Uterus
 - Ovary; fallopian tube
- 75 **All colon sites:**
 - Urinary bladder
 - Gallbladder
 - Adrenal gland
 - Diaphragm
 - Other segment(s) of colon via serosa
 - Fistula to skin
- 80 **FURTHER extension**
- 85 **Metastasis**
- 99 **UNKNOWN if extension or metastasis**

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes
- 1 **All colon subsites:**
 - Epicolic (adjacent to bowel wall)
 - Paracolic/pericolic
 - Colic, NOS
 - Nodule(s) in pericolic fat
- 2 **Cecum and Appendix:**
 - Cecal, anterior, posterior, NOS
 - Ileocolic
 - Right colic
- Ascending colon:**
 - Ileocolic
 - Right colic
 - Middle colic
- Transverse colon and flexures:**
 - Middle colic
 - Right colic for hepatic flexure only
 - Left colic for splenic flexure only
 - Inferior mesenteric for splenic flexure only
- Descending colon:**
 - Left colic
 - Sigmoid
 - Inferior mesenteric
- Sigmoid:**
 - Sigmoidal (sigmoid mesenteric)
 - Superior hemorrhoidal
 - Superior rectal
 - Inferior mesenteric
- 3 **Mesenteric, NOS**
 - Regional lymph node(s), NOS
-
- DISTANT Lymph Nodes
- 7 **Other than above**
-
- 8 **Lymph Nodes, NOS**
- 9 **UNKNOWN; not stated**

RECTOSIGMOID, RECTUM
154.0-154.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
998	Familial/multiple polyposis (M-8220/8221)	
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 05 (Adeno)carcinoma in head of polyp, stalk not invaded
- Invasive tumor confined to:**
- 10 Mucosa, NOS (incl. intramucosal)
- 11 Lamina propria
- 12 Muscularis mucosae
- 13 Head of polyp
- 14 Stalk of polyp
- 15 Polyp, NOS
- 16 Submucosa (superficial invasion)
- 20 Muscularis propria invaded
- 30 Localized, NOS
- 40 Invasion through muscularis propria or muscularis, NOS
Extension through wall, NOS
Perimuscular tissue invaded
(Sub)serosal tissue/fat invaded
- 45 Extension to adjacent (connective) tissue:
Mesentery (incl. mesenteric fat, mesocolon)--**rectosigmoid**
Pericolic fat--**rectosigmoid**
Rectovaginal septum--**rectum**
Perirectal fat--**all sites**
- 50 Invasion of/through serosa (mesothelium)
- 55 (45) + (50)

Note: Ignore intraluminal extension to adjacent segment(s) of colon/rectum and code depth of invasion or extracolonic spread as indicated.

EXTENSION (cont'd)

LYMPH NODES

<p>60 Rectosigmoid: Small intestine Cul de sac (rectouterine pouch) Pelvic wall</p> <p>Rectum: Rectovesical fascia, male Bladder, male Prostate Ductus deferens Seminal vesicle(s) Vagina Cul de sac (rectouterine pouch) Pelvic wall Skeletal muscle of pelvic floor</p> <p>70 Rectosigmoid: Prostate Uterus Ovary; fallopian tube Bladder Ureter Colon via serosa</p> <p>Rectum: Uterus Bladder, female Urethra Bones of pelvis</p> <p>80 FURTHER extension</p> <p>85 Metastasis</p> <p>99 UNKNOWN if extension or metastasis</p>	<p> 0 No lymph node involvement - - - - - REGIONAL Lymph Nodes</p> <p>1 Rectosigmoid: Paracolic/pericolic Perirectal Nodule(s) in pericolic fat</p> <p>Rectum: Perirectal Nodule(s) in perirectal fat</p> <p>2 Rectosigmoid: Hemorrhoidal, superior or middle Left colic (incl. colic, NOS) Superior rectal Sigmoidal (sigmoid mesenteric) Inferior mesenteric</p> <p>Rectum: Sigmoidal (sigmoid mesenteric) Inferior mesenteric Hemorrhoidal, superior or inferior Sacral (lateral, presacral, sacral promontory (Gerota's), or NOS) Internal iliac (hypogastric)</p> <p>3 Mesenteric, NOS Regional lymph node(s), NOS - - - - - DISTANT Lymph Nodes</p> <p>7 Other than above - - - - -</p> <p>8 Lymph Nodes, NOS</p> <p>9 UNKNOWN; not stated</p>
--	--

ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM
 154.2-154.3, 154.8

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial	
	Invasive tumor confined to:	
10	Mucosa, NOS (incl. intramucosal)	
11	Lamina propria	
12	Muscularis mucosae	
16	Submucosa (superficial invasion)	
20	Muscularis propria (internal sphincter)	
30	Localized, NOS	
40	Rectal mucosa or submucosa Subcutaneous perianal tissue Perianal skin Skeletal muscles: Anal sphincter (external), levator ani Ischiorectal fat/tissue	
60	Perineum Vulva	
70	Bladder Urethra Vagina	
75	Prostate Cervix Uteri Corpus Uteri Broad ligament(s)	
80	FURTHER extension	
85	Metastasis	
99	UNKNOWN if extension or metastasis	

ANAL CANAL, ANUS NOS, OTHER PARTS OF RECTUM
154.2-154.3, 154.8

LYMPH NODES

- 0 No lymph node involvement
- - - - -
- REGIONAL Lymph Nodes
- 1 Anorectal; perirectal
- 2 Internal iliac (hypogastric) and
lateral sacral, unilateral
- 3 Superficial inguinal (femoral),
unilateral
- 4 (3) plus (1) or (2)
- 5 Bilateral internal iliac
(hypogastric), lateral
sacral, and/or superficial
inguinal (femoral)
- 6 Regional lymph node(s), NOS
- - - - -
- DISTANT Lymph Nodes
- 7 Other than above
- - - - -
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

LIVER, INTRAHEPATIC BILE DUCT(S)
155.0-155.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Single lesion (one lobe)
WITHOUT intrahepatic vascular invasion, incl. NOS
- 20 Single lesion (one lobe)
WITH intrahepatic vascular invasion
- 30 Multiple tumors (one lobe)
WITHOUT intrahepatic vascular invasion, incl. NOS
- 40 Multiple tumors (one lobe)
WITH intrahepatic vascular invasion
- 50 Confined to liver, NOS
Localized, NOS
- 60 More than one lobe
involved by contiguous growth (single lesion)
Extension to extrahepatic blood vessel(s): hepatic artery, vena cava, portal vein
- 65 Multiple (satellite) nodules in more than one lobe of liver or on surface of parenchyma
Satellite nodules, NOS
- 70 Extrahepatic bile duct(s)
Diaphragm
- 75 Parietal peritoneum
Gallbladder
Ligament(s): Falciiform, coronary, hepatogastric, hepatoduodenal, triangular
Lesser omentum
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LIVER, INTRAHEPATIC BILE DUCT(S)
155.0-155.1

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Hepatic: Hepatic pedicle, inferior
vena cava, hepatic artery, porta
hepatis (hilar)

5 Regional lymph node(s), NOS

DISTANT Lymph Nodes

6 Cardiac
Diaphragmatic: Pericardial
Posterior mediastinal, incl.
juxtaphrenic nodes
Aortic (para-, peri-, lateral)
Retroperitoneal, NOS

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

GALLBLADDER, OTHER AND BILIARY TRACT, NOS
 156.0, 156.8-156.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to:
 Mucosa, NOS
 Lamina propria
 Submucosa (superficial invasion)
- 20 Muscularis propria
- 30 Localized, NOS
- 40 Perimuscular connective tissue |
- 50 Invasion of/through serosa |
- 55 (40) + (50)
- 60 Extension into liver, NOS
- 61 Extension into liver ≤2 cm
- 62 Extension to one of the following:
 Extrahepatic bile duct(s), incl. ampulla of Vater
 Pancreas
 Omentum
 Duodenum; small intestine, NOS
- 65 Extension to one of the following:
 Large intestine
 Stomach
- 70 Extension into liver >2 cm
 Extension to two or more adjacent organs listed above in code 62 and/or code 65, OR |
 liver involvement with any organ above in code 62 and/or |
 code 65 |
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

GALLBLADDER, OTHER AND BILIARY TRACT, NOS
156.0, 156.8-156.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Cystic duct (node of the neck of
the gallbladder)
Pericholedochal (node around common
bile duct)
Hilar (in hilus of liver--in
hepatoduodenal ligament)
Node of the foramen of Winslow

2 Hepatic: Periportal,
periduodenal, peripancreatic
(near head of pancreas only)

3 Regional lymph node(s), NOS

5 Celiac

6 Mesenteric, superior

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

EXTRAHEPATIC BILE DUCT(S)
156.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Invasive tumor of bile duct(s) (cystic, hepatic, and common) confined to:
Mucosa, NOS
Lamina propria
Submucosa
- 20 Muscle wall (muscularis propria) |
- 30 Localized, NOS
- 40 Periductal/perimuscular connective tissue |
- 60 Duodenum |
Gallbladder
Pancreas
Liver, porta hepatis
- 65 Blood vessels: Portal vein, |
hepatic artery
Stomach
Colon
Omentum
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: Codes 156.8-156.9, biliary tract, NOS, are included with gallbladder, 156.0

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Cystic duct (node of the neck of
the gallbladder)
Pericholedochal (node around
common bile duct)
Node of the foramen of Winslow
Hilar (in the hepatoduodenal
ligament)

2 Hepatic: Periportal,
periduodenal,
peripancreatic (near head of
pancreas only)

3 Regional lymph node(s), NOS

5 Celiac

6 Mesenteric, superior

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

AMPULLA OF VATER
156.2

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial	
10	Invasive tumor confined to ampulla of Vater	
30	Localized, NOS	
40	Duodenum Extrahepatic bile ducts	
50	Tumor invasion into pancreas, incl. pancreatic duct, ≤2 cm	
60	Tumor invasion into pancreas >2 cm	
70	Other adjacent organs	
80	FURTHER extension	
85	Metastasis	
99	UNKNOWN if extension or metastasis	

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
- Peripancreatic
 - Hepatic
 - Infrapyloric
 - Subpyloric
 - Celiac
 - Pancreaticoduodenal
 - Superior mesenteric
 - Retroperitoneal
 - Lateral aortic
- Regional lymph node(s), NOS

- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PANCREAS: HEAD, BODY, AND TAIL
157.0-157.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Confined to pancreas |
- 30 Localized, NOS |
- 40 Extension to peripancreatic tissue, NOS
Fixation to adj. structures/NOS
- 45 Extrahepatic bile ducts (includes external right and left hepatic ducts, common hepatic duct, and common bile duct)
Ampulla of Vater
Duodenum
- 60 **Head of pancreas:** Stomach
Body and/or tail of pancreas: Left kidney; kidney, NOS
Left ureter
Spleen
Left adrenal (suprarenal) gland
Retroperitoneal soft tissue (retroperitoneal space)
- 65 **Head of pancreas:**
Major blood vessel(s): Hepatic, pancreaticoduodenal and/or gastroduodenal arteries, superior mesenteric artery/vein, portal vein
Transverse colon, incl. hepatic flexure
Peritoneum, mesentery, mesocolon, mesenteric fat
Greater/lesser omentum

Body and/or tail of pancreas:
Splenic flexure
Ileum and jejunum
Peritoneum, mesentery, mesocolon, mesenteric fat
Major blood vessel(s): Aorta, celiac artery, hepatic artery, splenic artery/vein, superior mesenteric artery/vein, portal vein

Note: Islets of Langerhans are distributed throughout the pancreas, and, therefore, any extension code 00-85 can be used.

PANCREAS: HEAD, BODY, AND TAIL
157.0-157.4

EXTENSION (cont'd)

- 66 Stomach from body and tail
- 67 Liver (incl. porta hepatis)
Gallbladder
- 70 **Head of pancreas** |
 - Kidney
 - Ureter
 - Adrenal gland
 - Retroperitoneum
 - Jejunum
 - Ileum
- Body and/or tail of pancreas** |
 - Right kidney/right ureter
 - Right adrenal gland
 - Diaphragm
 - Large intestine (other than splenic flexure)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement
-
- 1 REGIONAL Lymph Nodes
 - Peripancreatic
 - Hepatic
 - Infrapyloric (head only)
 - Subpyloric (head only)
 - Celiac (head only)
 - Superior mesenteric
 - Pancreaticocolial (body and tail only)
 - Splenic (body and tail only)
 - Retroperitoneal
 - Lateral aortic
 - Regional lymph node(s), NOS
-
- DISTANT Lymph Nodes
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PANCREAS, UNSPECIFIED
157.8-157.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive	
10	Invasive tumor confined to pancreas	
30	Localized, NOS	
40	Adjacent connective tissue	
60	Adjacent organs/structures	
80	FURTHER extension	
85	Metastasis	
99	UNKNOWN if extension or metastasis	

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Peripancreatic
 - Hepatic

 - Superior mesenteric
 - Retroperitoneal
 - Lateral aortic

 - Regional lymph node(s), NOS
-
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

RETROPERITONEUM AND PERITONEAL SITES
158.0, 158.8-158.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10	Tumor confined to site of origin
30	Localized, NOS
40	Adjacent connective tissue
60	Adjacent organs/structures
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

RETROPERITONEUM AND PERITONEAL SITES
158.0, 158.8-158.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Subdiaphragmatic
 - Intra-abdominal
 - Paracaval
 - Pelvic
 - Regional lymph node(s), NOS
 -
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

ILL-DEFINED DIGESTIVE AND PERITONEAL SITES
 159.0, 159.8-159.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive
10	Invasion of submucosa
30	Localized, NOS
40	Adjacent connective tissue
60	Adjacent organs/structures
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

ILL-DEFINED DIGESTIVE AND PERITONEAL SITES
159.0, 159.8-159.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Subdiaphragmatic
 - Intra-abdominal
 - Paracaval
 - Pelvic
 - Regional lymph node(s), NOS-----
- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

NASAL CAVITY, MIDDLE EAR
160.0, 160.1

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive
10 Invasive tumor confined to site of origin
30 Localized, NOS
40 Adjacent connective tissue |
60 Adjacent organs/structures |
80 FURTHER extension
85 Metastasis
99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

MAXILLARY SINUS
160.2

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to mucosa of maxillary antrum (sinus)
- 30 Localized, NOS
- 40 Invasion of infrastructure:
 - Palatine bone
 - Palate, hard
 - Middle nasal meatus
 - Nasal cavity (lateral wall, floor, septum, turbinates)
- 60 Invasion of suprastructure:
 - Skin of cheek
 - Floor or posterior wall of maxillary sinus
 - Floor or medial wall of orbit
 - Ethmoid sinus, anterior
- 70 Nasopharynx |
 - Ethmoid sinus, posterior
 - Sphenoid sinus
 - Palate, soft
 - Base of skull
 - Cribiform plate
 - Pterygomaxillary or temporal fossa
 - Orbital contents, including eye
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Submental
Submandibular (submaxillary)
Internal jugular (upper and
lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
Retropharyngeal
Cervical, NOS
Regional lymph node(s), NOS

1 One positive ipsilateral node
 ≤3 cm in greatest diameter

2 One positive ipsilateral node
 >3-6 cm in greatest diameter

3 Multiple positive ipsilateral
 nodes ≤6 cm

4 Ipsilateral, node size not stated

5 Bilateral and/or contralateral
 positive nodes ≤6 cm or size
 not stated

6 Any positive node(s),
 at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

ACCESSORY (Paranasal) SINUSES
(excl. Maxillary Sinuses)
160.3-160.5, 160.8-160.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive tumor confined to mucosa in one of the following:
Ethmoid air cells (sinus), unilateral
Frontal sinus
Sphenoid sinus
- 30 Localized, NOS
- 40 More than one accessory sinus invaded |
Destruction of bony wall of sinus
- 50 Palate |
Nasal cavity (floor, septum, turbinates)
- 60 Bone: Orbital structures, |
facial bones, pterygoid fossa, zygoma, maxilla
- 70 Nasopharynx |
Muscles: Masseter, pterygoid
Soft tissue
Skin
Brain, incl. cranial nerves
Orbital contents, including eye
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

ACCESSORY (Paranasal) SINUSES
(excl. Maxillary Sinuses)
160.3-160.5, 160.8-160.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Retropharyngeal
Internal jugular (upper deep
cervical):
 jugulodigastric
 jugulo-omohyoid
Cervical, NOS
Regional lymph node(s), NOS

- 1 One positive ipsilateral node
 ≤3 cm in greatest diameter
- 2 One positive ipsilateral node
 >3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
 nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
 positive nodes ≤6 cm or size
 not stated
- 6 Any positive node(s),
 at least one >6 cm

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

LARYNX

161.0-161.3, 161.8-161.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Invasive tumor confined to:
 - Supraglottis** (one subsite):
 i.e., laryngeal (posterior) surface of epiglottis, aryepiglottic fold, arytenoid cartilage, or ventricular band (false cord)
 - Subglottis**
- 11 One vocal cord (**glottic tumor**)
- 12 Both vocal cords (**glottic tumor**)
- 20 Tumor involves: More than one subsite of **supraglottis**
- 30 Tumor involves adjacent region(s) of larynx
- 35 Impaired vocal cord mobility (**glottic tumor**)
- 40 Tumor limited to larynx WITH vocal cord fixation
- 50 Localized, NOS
- 60 Pre-epiglottic tissues
 - Postcricoid area
 - Pyriiform sinus
 - Hypopharynx, NOS
 - Vallecula
 - Base of tongue
- 70 Extension to/through thyroid or cricoid cartilage and/or oropharynx, cervical esophagus, soft tissues of neck, extrinsic (strap) muscles, skin
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note: AJCC includes lingual (anterior) surface of epiglottis (146.4) with larynx (161._).

LYMPH NODES

- 0 No lymph node involvement

REGIONAL Lymph Nodes (incl. contra-
lateral or bilateral nodes)
- Internal jugular (upper and
lower deep cervical) for glottic
and supraglottic:
jugulodigastric
jugulo-omohyoid
Anterior cervical: Prelaryngeal,
pretracheal, paratracheal,
laterotracheal (recurrent
laryngeal)
Submaxillary
Submental
Cervical, NOS
Regional lymph node(s), NOS
- 1 One positive ipsilateral node
≤3 cm in greatest diameter
- 2 One positive ipsilateral node
>3-6 cm in greatest diameter
- 3 Multiple positive ipsilateral
nodes ≤6 cm
- 4 Ipsilateral, node size not stated
- 5 Bilateral and/or contralateral
positive nodes ≤6 cm or size
not stated
- 6 Any positive node(s),
at least one >6 cm

DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

Note: If laterality is not
specified, assume nodes are
ipsilateral.

TRACHEA
162.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive
10 Invasive tumor confined to trachea
30 Localized, NOS
40 Adjacent connective tissue |
60 Adjacent organs/structures |
80 FURTHER extension
85 Metastasis
99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement
- - - - -
- 1 REGIONAL Lymph Nodes

- - - - -
- 7 DISTANT Lymph Nodes

- - - - -
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

LUNG, MAIN STEM BRONCHUS
162.2-162.5, 162.8-162.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

- 000 No primary tumor found
- 001 Microscopic focus or foci only
- 002 Malignant cells present in bronchopulmonary secretions

	<u>mm</u>	<u>cm</u>
003	≤3	≤0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+

- 998 Diffuse (entire lobe or lung)
- 999 Not stated

Note 1: Assume tumor ≥2 cm from carina if lobectomy is done.

Note 2: If no mention is made of the opposite lung on a chest x-ray, assume it is not involved.

Note 3: "Bronchopneumonia" is not the same thing as "obstructive pneumonitis" and should not be coded as such.

Note 4: Ignore pleural effusion which is negative for tumor.

Note 5: If at mediastinoscopy/x-ray the description is mediastinal mass/adenopathy, assume that it is mediastinal nodes.

Note 6: The words "no evidence of spread" or "remaining examination negative" are sufficient information to consider regional lymph nodes negative in the absence of any statement about nodes.

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Tumor confined to one lung (excl. primary in MSB)
- 20 Tumor involving main stem bronchus ≥2 cm from carina (primary in lung or MSB)
- 30 Localized, NOS
- 40 Extension to:
 - Pleura, visceral or NOS
 - Pulmonary ligament
 - Atelectasis/obstructive pneumonitis involving <entire lung (or NOS)
 - WITHOUT pleural effusion
- 50 Tumor of/involving main stem bronchus <2.0 cm from carina; or primary in the carina
- 60 Extension to:
 - Chest (thoracic) wall
 - Parietal pericardium or NOS
 - Parietal (mediastinal) pleura
 - Brachial plexus from superior sulcus or Pancoast tumor (superior sulcus syndrome)
 - Diaphragm
 - Atelectasis/obstructive pneumonitis involving entire lung

EXTENSION (cont'd)

- 70 Carina; trachea; esophagus
Mediastinum, extrapulmonary
or NOS
Major blood vessel(s):
Pulmonary artery or vein;
superior vena cava (SVC
syndrome); aorta
Nerve(s):
Recurrent laryngeal
(vocal cord paralysis);
vagus; phrenic; cervical
sympathetic (Horner's
syndrome)
- 71 Heart
Visceral pericardium
- 72 Malignant pleural effusion
Pleural effusion, NOS
- 73 Adjacent rib
- 75 Sternum
Vertebra(e)
Skeletal muscle
Skin of chest
- 78 Contralateral lung/MSB
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
or metastasis

LYMPH NODES

- 0 No lymph node involvement

- REGIONAL Lymph Nodes (Ipsilateral)
- 1 Intrapulmonary
Hilar (pulmonary root)
Peribronchial
- 2 Subcarinal; carinal
Mediastinal, anterior,
posterior, NOS
Paratracheal; pretracheal
Paraesophageal
Aortic (para-, peri-) (above
diaphragm)
- 5 Regional lymph node(s), NOS
- 6 Contralateral hilar or medias-
tinal (incl. bilateral)
Supraclavicular (transverse
cervical)
Scalene
-
- DISTANT Lymph Nodes
- 7 Other than above (incl. cervical
neck nodes)

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

Note 7: AJCC (TNM) classifies
the lymph nodes in code 6 to N3.

PLEURA

163.0-163.1, 163.8-163.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 10 Invasive tumor (mesothelioma) |
confined to pleura
- 20 Mesothelioma WITH nodule(s) beneath
visceral pleural surface
- 30 Localized, NOS
- 40 Adjacent connective tissue |
- 50 Mesothelioma nodule(s) which have
broken through the visceral
pleural surface to the lung
surface; lung involvement, NOS
- 60 Extension to adjacent
organs/structures such as:
Chest wall
Rib
Heart muscle
Diaphragm
- 70 Mesothelioma WITH malignant
pleural fluid; pleural
effusion |
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

PLEURA
163.0-163.1, 163.8-163.9

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

HEART, MEDIASTINUM
 164.1-164.3, 164.8-164.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10	Invasive tumor confined to site of origin	
30	Localized, NOS	
40	Adjacent connective tissue	
60	Adjacent organs/structures	
80	FURTHER extension	
85	Metastasis	
99	UNKNOWN if extension or metastasis	

Note: Code 164.0, thymus, is included with other endocrine glands, 194._.

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS
 165.0, 165.8-165.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10	Invasive tumor confined to site of origin
30	Localized, NOS
40	Adjacent connective tissue
60	Adjacent organs/structures
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

**ILL-DEFINED RESPIRATORY SITES AND INTRATHORACIC ORGANS
165.0, 165.8-165.9**

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BONE
170.0-170.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10 Invasive tumor confined to cortex of bone

20 Extension beyond cortex to periosteum (no break in periosteum)

30 Localized, NOS

40 Extension beyond periosteum to surrounding tissues, incl. adjacent skeletal muscle(s)

60 Adjacent Bone

70 Skin

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

CONNECTIVE AND OTHER SOFT TISSUE
 171.0, 171.2-171.9

SIZE OF PRIMARY TUMOR
 (from pathology report; operative
 report; radiographic report;
 physical examination--in
 priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

10	Invasive tumor confined to site/tissue of origin	
30	Localized, NOS	
40	Adjacent connective tissue	
60	Adjacent organs/structures	
80	FURTHER extension	
85	Metastasis	
99	UNKNOWN if extension or metastasis	

LYMPH NODES

- 0 No lymph node involvement

1 REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)

Head and Neck - All subsites:
Cervical

Lip: Preauricular, facial, submental, submandibular

Eyelid/canthus:
Preauricular, facial, submandibular, infra-auricular

External ear/auditory canal:
Pre-/post-auricular (mastoid)

Face, Other (cheek, chin, forehead, jaw, nose and temple): Preauricular, facial, submental, submandibular

Scalp/neck:
Preauricular, occipital, spinal accessory (posterior cervical); mastoid (post-auricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

Upper trunk

Cervical, supraclavicular, Internal mammary, axillary

Lower trunk

Femoral (superficial inguinal)

Arm/shoulder

Axillary
Spinal accessory for shoulder
Epitrochlear for hand/forearm

Leg/hip

Femoral (superficial inguinal)
Popliteal for heel and calf

All Sites

Regional lymph node(s), NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma,
 Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
 173.0-173.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative
 report; physical examination--in
 priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive;
 intraepidermal;
 Bowen's disease
- 10 Lesion(s) confined to dermis
For eyelid: Minimal infiltra-
 tion of dermis (not invading |
 tarsal plate)
- 20 **For eyelid:** Infiltrates deeply
 into dermis (invading tarsal |
 plate)
- 30 Involves full eyelid thickness
- 40 Localized, NOS
- 50 Subcutaneous tissue (through
 entire dermis)
- 60 Adjacent structures for eyelid |
- 70 Underlying cartilage, bone, |
 skeletal muscle
 Orbit for eyelid |
- 75 Metastatic skin lesion(s)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note 1: In the case of multiple |
 simultaneous tumors, code tumor |
 with greatest extension.

Note 2: Skin ulceration does not |
 alter the Extent of Disease clas- |
 sification.

Note 3: Skin of genital sites is |
 not included in this scheme. |
 These sites are skin of vulva |
 (184.1-184.4), skin of penis |
 (187.1, 187.2, 187.4) and skin of |
 scrotum (187.7). |

SKIN (excl. Malignant Melanoma, Kaposi's Sarcoma,
 Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
 173.0-173.9

LYMPH NODES

- 0 No lymph node involvement
-
- 1 REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)
- Head and Neck - All subsites:
- Cervical
- Lip: Preauricular, facial, submental, submandibular
- Eyelid/canthus: Preauricular, facial, submandibular, infra-auricular
- External ear/auditory canal: Pre-/post-auricular (mastoid)
- Face, Other (cheek, chin, forehead, jaw, nose and temple): Preauricular, facial, submental, submandibular
- Scalp/neck: Preauricular, occipital, spinal accessory (posterior cervical); mastoid (post-auricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

- Upper trunk
- Cervical, supraclavicular, internal mammary, axillary
- Lower trunk
- Femoral (superficial inguinal)
- Arm/shoulder
- Axillary
- Spinal accessory for shoulder
- Epitrochlear for hand/forearm
- Leg/hip
- Femoral (superficial inguinal)
- Popliteal for heel and calf
- All sites
- Regional lymph node(s), NOS
-
- DISTANT Lymph Nodes
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM
 173.0-173.9, 184.1-184.4, 187.1-187.2, 187.4, 187.7
 (M-8720-8790)

<u>MEASURED THICKNESS (Depth)* OF TUMOR</u> (Breslow's measurement)	<u>EXTENSION</u>
<u>Record Actual Measurement</u> (in mm) from Pathology Department	
000 No mass; no tumor found	00 IN SITU: Noninvasive; intraepithelial Clark's level I Basement membrane of the epidermis is intact.
mm	
001 0.01	10 Papillary dermis invaded Clark's level II
002 0.02	11 (10) WITH ulceration
...	
...	20 Papillary-reticular dermal interface invaded Clark's level III
074 0.74	
075 0.75	21 (20) WITH ulceration
076 0.76	
...	
...	30 Reticular dermis invaded Clark's level IV
103 1.03	
104 1.04	31 (30) WITH ulceration
105 1.05	
...	
...	40 Skin/dermis, NOS Localized, NOS
990 9.90+	
999 Not stated	41 (40) WITH ulceration
	50 Subcutaneous tissue invaded (through entire dermis) Clark's level V
	51 (50) WITH ulceration
*Thickness, NOT size, is coded.	60 Satellite nodule(s), NOS
<u>Note:</u> For melanoma of sites other than those above, use site-specific schemes.	62 Satellite nodule(s), ≤ 2 cm from primary tumor
	64 (50-51) plus (60) or (62)
	70 Underlying cartilage, bone, skeletal muscle
	80 FURTHER extension
	85 Metastasis to skin or subcutaneous tissue beyond regional lymph nodes
	87 Visceral metastasis; metastasis, NOS
	99 UNKNOWN if extension or metastasis

MALIGNANT MELANOMA OF SKIN, VULVA, PENIS, SCROTUM
 173.0-173.9, 184.1-184.4, 187.1-187.2, 187.4, 187.7
 (M-8720-8790)

LYMPH NODES

0 No lymph node involvement
 - - - - -

REGIONAL by primary site (bilateral or contralateral for head, neck, trunk)

Head and Neck - All subsites:
 Cervical

Lip: Preauricular, facial, submental, submandibular

Eyelid/canthus: Preauricular, facial, submandibular, infra-auricular

External ear/auditory canal: Pre-/post-auricular (mastoid)

Face, Other (cheek, chin, forehead, jaw, nose, and temple): Preauricular, facial, submental, submandibular

Scalp/neck: Preauricular, occipital, spinal accessory (post. cervical); mastoid (postauricular) for scalp; submental, supraclavicular, axillary for neck

LYMPH NODES (cont'd)

Upper trunk

Cervical, supraclavicular, internal mammary, axillary

Lower trunk

Femoral (superficial inguinal)

Arm/shoulder

Axillary
 Spinal accessory for shoulder
 Epitrochlear for hand/forearm

Leg/hip

Femoral (superficial inguinal)
 Popliteal for heel and calf

Vulva/penis/scrotum

Femoral (superficial inguinal)
 Deep inguinal

All sites

Regional, NOS

- 1 Lymph node(s) metastasis ≤ 3 cm |
- 2 Lymph node(s) metastasis > 3 cm |
- 3 In-transit metastasis
 (Satellite lesion(s)/subcutaneous nodule(s) > 2 cm from the primary tumor, but not beyond the site of primary lymph node drainage)
- 4 (2) plus (3)
- 5 Size not given

- - - - -
 DISTANT Lymph Nodes

7 Other than above

- - - - -
 8 Lymph Nodes, NOS

9 UNKNOWN; not stated

MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM |
 173.0-173.9, 184.1-184.4, 187.1-187.2, 187.4, 187.7 |
 (M-9700-9701)

PERIPHERAL BLOOD INVOLVEMENT

EXTENSION

000 No peripheral blood involvement

Plaques, papules, or erythematous patches ("plaque stage"):

Atypical circulating cells in peripheral blood:

10 <10% of skin surface, no tumors

001 <5%

20 ≥10% of skin surface, no tumors

002 >5%

003 % not stated

25 % of body surface not stated, no tumors

999 Not applicable

30 Skin involvement, NOS: extent not stated, no tumors
 Localized, NOS

Note: In approximating body surface, the palmar surface of the hand, including digits, is about 1%.

50 One or more tumors (tumor stage)

70 Generalized erythroderma (>50% of body involved with diffuse redness); Sezary's syndrome

85 Visceral (non-cutaneous, extra-nodal) involvement (other than peripheral blood)

99 UNKNOWN; not stated

Source: Developed by the Mycosis Fungoides Cooperative Group

MYCOSIS FUNGOIDES AND SEZARY'S DISEASE OF SKIN, VULVA, PENIS, SCROTUM |
173.0-173.9, 184.1-184.4, 187.1-187.2, 187.4, 187.7 |
(M-9700-9701)

LYMPH NODES

0 No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement) |

REGIONAL Lymph Nodes

1 Clinically enlarged palpable regional lymph node(s) (adenopathy), and either pathologically negative regional nodes or no pathological statement |

2 No clinically enlarged palpable regional lymph nodes(s) (adenopathy); pathologically positive regional lymph node(s)

3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive regional lymph nodes

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

BREAST

174.0-174.6, 174.8-174.9, 175.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination; mammography examination--in priority order; if multiple masses, code largest diameter)

000	No mass; no tumor found; no Paget's disease	
001	Microscopic focus or foci only	
002	Mammography/xerography diagnosis only with no size given (tumor not clinically palpable)	
	<u>mm</u>	<u>cm</u>
003	≤3	≤0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
997	Paget's Disease of nipple with no demonstrable tumor	
998	Diffuse; widespread: 3/4's or more of breast; inflammatory carcinoma	
999	Not stated	

Note 1: Changes such as dimpling of the skin, tethering, and nipple retraction are caused by tension on Cooper's ligament(s), not by actual skin involvement. They do not alter the classification.

Note 2: Consider adherence, attachment, fixation, induration, and thickening as clinical evidence of extension to skin or subcutaneous tissue; code '20'.

Note 3: Consider "fixation, NOS" as involvement of pectoralis muscle; code '30'.

EXTENSION

- 00 IN SITU: Noninfiltrating; intraductal WITHOUT infiltration; lobular neoplasia
- 05 Paget's disease (WITHOUT underlying tumor)
- 10 Confined to breast tissue and fat including nipple and/or areola
- 20 Invasion of subcutaneous tissue
Skin infiltration of primary breast including skin of nipple and/or areola
Local infiltration of dermal lymphatics adjacent to primary tumor involving skin by direct extension
- 30 Invasion of (or fixation to) pectoral fascia or muscle; deep fixation; attachment or fixation to pectoral muscle or underlying tissue
- 40 Invasion of (or fixation to) chest wall, ribs, intercostal or serratus anterior muscles
- 50 Extensive skin involvement:
Skin edema, peau d'orange, "pigskin," en cuirasse, lenticular nodule(s), inflammation of skin, erythema, ulceration of skin of breast, satellite nodule(s) in skin of primary breast
- 60 (50) plus (40)
- 70 Inflammatory carcinoma, incl. diffuse (beyond that directly overlying the tumor) dermal lymphatic permeation or infiltration

Note 4:

If extension code is:	Behavior code must be:
00	2
05	2 or 3
10+	3

EXTENSION (cont'd)

- 80 FURTHER extension:
Skin over sternum, upper abdomen, axilla or opposite breast
- 85 Metastasis:
Bone, other than adjacent rib
Lung
Breast, contralateral--if metastatic
Adrenal gland
Ovary
Satellite nodule(s) in skin other than primary breast
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes (ipsilateral)
- Axillary
 - Level I/low: Adjacent to tail of breast
 - Level II/mid: Central, interpectoral, (Rotter's node)
 - Level III/high: Subclavicular, apical
- Intramammary
Nodule(s) in axillary fat
- Size of largest axillary node, ipsilateral (codes 1-4):
- 1 Micrometastasis (≤ 0.2 cm)
- 2 >0.2 - <2.0 cm, no extension beyond capsule
- 3 <2.0 cm WITH extension beyond capsule
- 4 ≥ 2.0 cm
- 5 Fixed/matted ipsilateral axillary nodes
- 6 Axillary/regional lymph nodes, NOS
Lymph nodes, NOS
- 7 Internal mammary node(s), ipsilateral
-
- DISTANT Lymph Nodes
- 8 Cervical, NOS
Contralateral/bilateral axillary and/or internal mammary
Infraclavicular
Supraclavicular (transverse cervical)
Other than above
-
- 9 UNKNOWN; not stated

CERVIX UTERI

180.0-180.1, 180.8-180.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Preinvasive; noninvasive; intraepithelial Cancer in situ WITH endocervical gland involvement FIGO Stage 0	
01	CIN* Grade III	
11	Minimal microscopic stromal invasion FIGO Stage IA1	
12	"Microinvasion" Tumor WITH invasive component ≤5 mm in depth, taken from the base of the epithelium, and ≤7 mm in horizontal spread FIGO Stage IA2	
20	Invasive cancer confined to cervix and tumor larger than that in code 12 FIGO Stage IB	
30	Localized, NOS; confined to cervix uteri or uterus, NOS	
31	FIGO Stage I, not further specified	
35	Corpus uteri	
40	Extension to: Upper 2/3's of vagina (incl. fornices and vagina/vaginal wall, NOS) Cul de sac (rectouterine pouch) FIGO Stage IIA	
50	Extension to: Parametrium (paracervical soft tissue) Ligaments: Broad, uterosacral, cardinal FIGO Stage IIB	
	*CIN = Cervical intraepithelial neoplasia	

Note 1: Involvement of anterior and/or posterior septum is coded as involvement of the vaginal wall.

Note 2: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 65.

Note 3: If the clinician says "adnexa palpated" but doesn't mention lymph nodes, assume lymph nodes are not involved.

Note 4: If either exploratory/definitive surgery is done with no mention of lymph nodes, assume nodes are negative.

CERVIX UTERI
180.0-180.1, 180.8-180.9

EXTENSION (cont'd)

LYMPH NODES

60	Extension to: Lower 1/3 of vagina Rectal and/or bladder wall or NOS Bullous edema of bladder mucosa Ureter, intra- and extramural FIGO Stage IIIA		0 No lymph node involvement - - - - - 1 REGIONAL Lymph Nodes Paracervical Parametrial Iliac: Common Internal (hypogastric): Obturator External Pelvic, NOS Sacral (lateral, presacral, sacral promontory (Gerota's), uterosacral, or NOS)
65	Extension to: Pelvic wall(s) Hydronephrosis or nonfunctioning kidney (except if other cause) FIGO Stage IIIB		Regional lymph node(s), NOS - - - - - DISTANT Lymph Nodes
70	Extension to rectal or bladder <u>mucosa</u> FIGO Stage IVA		6 Aortic (para-, peri-, lateral) 7 Other than above - - - - -
80	FURTHER extension beyond true pelvis FIGO Stage IVA, not further specified		8 Lymph Nodes, NOS
85	Metastasis FIGO Stage IVB		9 UNKNOWN; not stated
99	UNKNOWN if extension or metastasis		

CORPUS UTERI

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR THE CORPUS UTERI

Careful attention must be given to the use of the term "confined to endometrium" for corpus uteri.

- 1) Determine if the tumor is confined to the columnar epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the stroma (lamina propria), in which case it is localized and is coded to invasion of the stroma.

The endometrium (mucosa) consists of:

The EPITHELIAL LAYER contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

There is NO MUSCULARIS MUCOSAE or SUBMUCOSA in the endometrium.

The MYOMETRIUM (muscularis) is composed of three layers of smooth muscle fibers; it constitutes the wall of the organ.

The SEROSA, the outermost layer covering the corpus uteri, is a serous membrane, part of the visceral peritoneum.

CORPUS UTERI

PRIMARY SITE	ENDOMETRIUM (mucosa)		MYOMETRIUM (3 layers)	SEROSA
Corpus Uteri (182._)	Columnar Epithelium	B A S E : M E M : :	Stroma (lamina propria) Yes	Yes
	Yes			

CORPUS UTERI, PLACENTA AND UTERUS, NOS
 179.9, 181.9, 182.0-182.1, 182.8

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+

999 Not stated

EXTENSION

00 IN SITU: Preinvasive, noninvasive
 FIGO Stage 0

No sounding done; sounding, NOS

10 FIGO Stage I not further specified
 11 Confined to endometrium (stroma)

Extension to:

12 Myometrium--inner half
 13 Myometrium--outer half
 14 Myometrium--NOS
 15 Serosa

Sounding of uterine cavity is ≤8.0 cm in length

20 FIGO Stage IA not further specified
 21 Confined to endometrium (stroma)

Extension to:

22 Myometrium--inner half
 23 Myometrium--outer half
 24 Myometrium--NOS
 25 Serosa

Sounding of uterine cavity is >8.0 cm in length

30 FIGO Stage IB not further specified
 31 Confined to endometrium (stroma)

Extension to:

32 Myometrium--inner half
 33 Myometrium--outer half
 34 Myometrium--NOS
 35 Serosa

Note 1: Adnexa=tubes, ovaries and ligament(s)

Note 2: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 60.

Note 3: If the clinician says "adnexa palpated" but doesn't mention lymph nodes, assume lymph nodes are not involved.

Note 4: If either exploratory/definitive surgery is done with no mention of lymph nodes, assume nodes are negative.

40 Localized, NOS

50 Cervix uteri, incl. endocervix invaded
 FIGO Stage II

CORPUS UTERI, PLACENTA AND UTERUS, NOS
179.9, 181.9, 182.0-182.1, 182.8

EXTENSION (cont'd)

LYMPH NODES

<p>60 Extension within true pelvis: Parametrium Ligaments: Broad, round, uterosacral Pelvic wall(s) Ovary(ies) and/or fallopian tube(s) Rectal and/or bladder wall or NOS Vagina FIGO Stage III</p>	<p>0 No lymph node involvement ----- REGIONAL Lymph Nodes</p> <p>1 Parametrial Paracervical Iliac: Common Internal (hypogastric): Obturator External Pelvic, NOS Sacral (lateral, presacral, sacral promontory (Gerota's), uterosacral, or NOS)</p>
<p>70 Extension to rectal or bladder <u>mucosa</u> FIGO Stage IVA</p>	<p>2 Aortic (para-, peri-, lateral)</p>
<p>80 Extension beyond true pelvis FIGO Stage IVA, not further specified</p>	<p>5 Regional Lymph Nodes, NOS ----- DISTANT Lymph Nodes</p>
<p>85 Metastasis FIGO Stage IVB</p>	<p>6 Superficial inguinal</p>
<p>99 UNKNOWN if extension or metastasis</p>	<p>7 Other than above (incl. deep inguinal) -----</p> <p>8 Lymph Nodes, NOS</p> <p>9 UNKNOWN; not stated</p>

OVARY
183.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

SIZE

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

Note 1: Code size of tumor, not size of the cyst.

Note 2: Ascites WITH malignant cells changes FIGO Stages I and II to IC and IIC, respectively. Ascites, NOS is considered negative.

Note 3: Peritoneal implants outside the pelvis (codes 70-72) must be microscopically confirmed.

EXTENSION

- 00 IN SITU: Preinvasive; noninvasive; intraepithelial
- 10 Tumor limited to one ovary, capsule intact, no tumor on ovarian surface
FIGO Stage IA
- 20 Tumor limited to both ovaries, capsule(s) intact, no tumor on ovarian surface
FIGO Stage IB
- 30 Localized, NOS; unknown if capsule(s) ruptured or one or both ovaries involved
FIGO Stage I, not further specified
- 40 Tumor limited to ovary(ies), capsule(s) ruptured or tumor on ovarian surface
FIGO Stage IC
- 41 Tumor limited to ovary(ies) WITH malignant cells in ascites or peritoneal washings
FIGO Stage IC
- 42 (40) plus (41)
FIGO Stage IC, not further specified
- 50 Extension to or implants on:
Uterus
Fallopian tube(s)
Adnexa, NOS
FIGO Stage IIA
- 60 Extension to or implants on:
Pelvic wall
Pelvic tissue (broad ligament, adjacent peritoneum--mesovarium)
FIGO Stage IIB
- 62 (50) and/or (60) WITH malignant cells in ascites or peritoneal washings
FIGO Stage IIC

EXTENSION (cont'd)

LYMPH NODES

<p>65 FIGO Stage II, not further specified</p>	<p>0 No lymph node involvement</p> <p>-----</p>
<p>70 Microscopic peritoneal implants beyond pelvis, including peritoneal surface of liver FIGO Stage IIIA</p>	<p>REGIONAL Lymph Nodes (incl. contra-lateral or bilateral nodes)</p>
<p>71 Macroscopic peritoneal implants beyond pelvis, ≤2 cm in diameter, including peritoneal surface of liver FIGO Stage IIIB</p>	<p>1 Iliac: Common Internal (hypogastric): Obturator External Lateral sacral Pelvic, NOS</p>
<p>72 Peritoneal implants beyond pelvis, >2 cm in diameter, including peritoneal surface of liver FIGO Stage IIIC</p>	<p>2 Aortic (para-, peri-, lateral) Retroperitoneal, NOS</p>
<p>75 Peritoneal implants, NOS FIGO Stage III, not further specified</p>	<p>3 Inguinal</p> <p>4 (2) plus (1) and/or (3)</p> <p>5 Regional Lymph Nodes, NOS</p> <p>-----</p> <p>DISTANT Lymph Nodes</p>
<p>80 FURTHER extension</p>	<p>7 Other than above</p> <p>-----</p>
<p>85 Metastasis, including: Liver parenchymal metastasis Pleural fluid (positive cytology) FIGO Stage IV</p>	<p>8 Lymph Nodes, NOS</p> <p>9 UNKNOWN; not stated</p>
<p>99 UNKNOWN if extension or metastasis</p>	

Note 4: If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately (60-62) or (70-72). If the location is not specified, code as outside the pelvis (70-72 or 75).

FALLOPIAN TUBE AND BROAD LIGAMENT
 183.2-183.5, 183.8-183.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Tumor confined to tissue or organ of origin
- 30 Localized, NOS
- 40 Ovary, ipsilateral |
 Corpus uteri; uterus, NOS
- 50 Peritoneum |
 Fallopian tube for ligaments
 Broad ligament, ipsilateral
 for fallopian tube
 Mesosalpinx, ipsilateral
- 70 Omentum |
 Cul de sac (rectouterine pouch)
 Sigmoid
 Rectosigmoid
 Small intestine
 Ovary, contralateral
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

FALLOPIAN TUBE AND BROAD LIGAMENT
183.2-183.5, 183.8-183.9

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

1 Iliac: Common
Internal (hypogastric):
Obturator
External
Lateral sacral
Pelvic, NOS

2 Aortic (para-, peri-, lateral)
Retroperitoneal, NOS

3 Inguinal

4 (2) plus (1) and/or (3)

5 Regional Lymph Nodes, NOS

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

VAGINA
184.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- 10 Invasive cancer confined to: Submucosa (stroma) FIGO Stage I |
- 20 Musculature involved
- 30 Localized, NOS
- 40 Extension to:
 - Paravaginal soft tissue
 - Cervix
 - Vulva
 - Vesicovaginal septum
 - Rectovaginal septum
 FIGO Stage II |
- 50 Extension to:
 - Bladder wall or NOS
 - Rectal wall or NOS
 - Cul de sac (rectouterine pouch)
 FIGO Stage II |
- 60 Extension to pelvic wall
FIGO Stage III |
- 70 Extension to bladder or rectal mucosa
FIGO Stage IVA |
- 80 Extension beyond true pelvis
Extension to urethra
FIGO Stage IVA, not further specified |
- 85 Metastasis
FIGO Stage IVB |
- 99 UNKNOWN if extension or metastasis

Note: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 60.

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Upper two-thirds of vagina:

1 Pelvic lymph nodes:

Iliac: Common
 Internal (hypogastric)
 External
Sacral promontory
Pelvic, NOS

Lower third of vagina:

2 Ipsilateral inguinal lymph node(s)

3 Bilateral inguinal lymph node(s)

Both parts of vagina:

5 Regional lymph node(s), unknown whether primary is in upper or lower vagina

DISTANT Lymph Nodes

6 Inguinal (upper two-thirds only)
Aortic (para-, peri-, lateral)
Retroperitoneal, NOS

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

VULVA (incl. Skin of Vulva)
(excl. Malignant Melanoma, Kaposi's Sarcoma,
Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
184.1-184.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative
report; endoscopic examination;
physical examination--in
priority order)

EXTENSION

000 No mass; no tumor found
001 Microscopic focus or foci only

00 IN SITU: Noninvasive; Bowen's
disease, intraepidermal
FIGO Stage 0

10 Invasive cancer confined to:
Submucosa
Musculature

mm cm

FIGO Stage I if size ≤2.0 cm

002 ≤2 ≤0.2

003 3 0.3

FIGO Stage II if size >2.0 cm

...

30 Localized, NOS

009 9 0.9

010 10 1.0

60 Extension to:

...

Vagina

...

Urethra

099 99 9.9

Perineum

100 100 10.0

Perianal skin

...

Anus

990 990+ 99.0+

FIGO Stage III

999 Not stated

70 Rectal mucosa
Perineal body

75 Extension to:
Upper urethral mucosa
Bladder mucosa
Pelvic bone
FIGO Stage IVA

80 FURTHER extension

85 Metastasis
FIGO Stage IVB

99 UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of
vulva is included in the melanoma
scheme.

Note 2: Mycosis fungoides (M-9700)
and Sezary's disease (M-9701) of
vulva are included in the mycosis
fungoides scheme.

VULVA (incl. Skin of Vulva)
(excl. Malignant Melanoma, Kaposi's Sarcoma,
Mycosis Fungoides, Sezary's Disease, and Other Lymphomas
184.1-184.4

LYMPH NODES

- 0 No lymph node involvement

- REGIONAL Lymph Nodes (incl. contra- |
lateral or bilateral) |
- 1 Superficial inguinal (femoral)
Deep inguinal, Rosenmuller's
or Cloquet's node
Regional lymph nodes, NOS
- 2 (1) WITH fixation or ulceration
- 3 External iliac
Internal iliac (hypogastric)
Pelvic, NOS
- 4 (3) WITH fixation or ulceration

- DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

**OTHER FEMALE GENITAL ORGANS
184.8-184.9**

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive;
intraepithelial

10 Confined to site of origin

30 Localized, NOS

40 Adjacent connective tissue |

60 Adjacent organs/structures |

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

**OTHER FEMALE GENITAL ORGANS
184.8-184.9**

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes

- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

PROSTATE GLAND
185.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
009	9	0.9
010	10	1.0
...		
099	99	9.9
100	100	10.0
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intraepithelial
- Incidentally found microscopic carcinoma (latent)**
- 10 Number of foci not specified (A)
- 11 ≤3 microscopic foci (A1 Focal)
- 12 >3 microscopic foci (A2 Diffuse)
- 20 Palpable nodule(s) confined to prostate (intracapsular)--one lobe (B)
- 25 Multiple nodules confined to prostate--more than one lobe (B)
- 30 Localized, NOS; confined to prostate, NOS (B, not further specified)
- 40 Invasion of prostatic capsule (C1)
- 50 Extension to periprostatic tissue (C1):
 - Extracapsular extension (beyond prostatic capsule)
 - Extraprostatic urethra (membranous)
 - Bladder neck and/or prostatic apex
 - Through capsule, NOS
- 55 Extension to seminal vesicle(s) (C2)
- 56 Extension to periprostatic tissue, NOS (C, not further specified)
- 60 Extension to or fixation of other adjacent structures:
 - Rectovesical (Denonvilliers') fascia
 - Bladder, NOS; ureter(s)
 - Rectum
 - Skeletal muscle (levator ani)
 - Fixation, NOS

Note 1: Involvement of prostatic urethra does not alter the extension code.

Note 2: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a statement of involvement, code as 70.

Note 3: If D1-D2 is based on involvement of lymph nodes only, code under lymph nodes and not extension.

Note 4: B can be further classified: B1, Small, discrete nodule(s) ≤1.5 cm, and B2 Nodule(s) >1.5 cm or in more than one lobe.

Source: The American Urological Association Staging System (A-D)

EXTENSION (cont'd)

LYMPH NODES

70	Pelvic bone Pelvic wall(s)		0 No lymph node involvement -----
80	FURTHER extension to bone, soft tissue or other organs (D2)		REGIONAL Lymph Nodes (incl. contra- lateral or bilateral nodes)
85	Metastasis (D2) D, not further specified		Periprostatic Iliac: Internal (hypogastric): Obturator External Iliac, NOS
99	UNKNOWN if extension or metastasis		Pelvic, NOS Sacral (lateral, presacral, sacral promontory (Gerota's), or NOS) Regional lymph node(s), NOS 1 Single lymph node ≤2 cm 2 Single lymph node >2-5 cm OR multiple nodes, none greater than 5 cm 3 Lymph node(s), at least one >5 cm 5 Size not stated ----- DISTANT Lymph Nodes 6 Aortic (para-, peri-, lateral, lumbar) Retroperitoneal, NOS Common iliac Inguinal, superficial (femoral) and/or deep 7 Other than above ----- 8 Lymph Nodes, NOS 9 UNKNOWN; not stated

TESTIS
186.0, 186.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	mm	cm
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; intratubular
- 10 Confined to body of testis/tunica albuginea; rete testis
- 20 Tunica vaginalis involved
Surface implants
- 30 Localized, NOS
Tunica, NOS
- 40 Epididymis
- 50 Spermatic cord, ipsilateral
Vas deferens
- 60 Scrotum, ipsilateral, incl. dartos muscle
- 70 Extension to scrotum, contralateral
Ulceration of scrotum
- 75 Penis
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

REGIONAL Lymph Nodes (incl. contra- |
lateral or bilateral nodes) |
- Paracaval
Aortic (para-, peri-, lateral)
External iliac
Retroperitoneal, NOS
Pelvic, NOS
Regional lymph node(s), NOS
- 1 Single lymph node ≤ 2 cm
- 2 Single lymph node $>2-5$ cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated
- DISTANT Lymph Nodes
- 6 Inguinal nodes, superficial |
(femoral) and/or deep |
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

Note: Regardless of previous in- |
guinal or scrotal surgery, invol- |
vement of inguinal nodes is al- |
ways considered distant by SEER. |

PREPUCE, PENIS NOS, AND GLANS PENIS (excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease, and Other Lymphomas)
 187.1-187.2, 187.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive; Bowen's disease; intraepithelial
- 05 Noninvasive verrucous carcinoma
- 10 Invasive tumor limited to subepithelial connective tissue, but not involving corpus spongiosum or cavernosum
- 30 Localized, NOS
- 40 Corpus cavernosum
Corpus spongiosum
- 50 Satellite nodule(s) on prepuce or glans
- 60 Urethra
Prostate
- 70 Adjacent structures
Skin: Pubic, scrotal, abdominal, perineum
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of penis is included in the melanoma scheme.

Note 2: Mycosis fungoides (M-9700) or Sezary's disease (M-9701) of penis is included in the mycosis fungoides scheme.

**PREPUCE, PENIS NOS, AND GLANS PENIS (excl. Malignant Melanoma,
Kaposi's Sarcoma, Mycosis Fungoides, Sezary's Disease,
and Other Lymphomas)**
187.1-187.2, 187.4

LYMPH NODES

- 0 No lymph node involvement

REGIONAL Lymph Nodes
- 1 SINGLE superficial inguinal
(femoral)
- 2 Multiple OR bilateral
superficial inguinal
(femoral)
- 3 Deep inguinal: Rosenmuller's
or Cloquet's node
- 5 Regional lymph node(s), NOS
- 6 External iliac
Internal iliac (hypogastric)
Pelvic nodes, NOS

DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BODY OF PENIS, SCROTUM, AND OTHER MALE GENITAL ORGANS
(excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis
Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum)
187.3, 187.5-187.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative
report; endoscopic examination;
physical examination--in
priority order)

000	No mass; no tumor found	
001	Microscopic focus or foci only	
	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00	IN SITU: Noninvasive; intraepithelial
10	Confined to site of origin
30	Localized, NOS
40	Adjacent connective tissue
60	Adjacent organs/structures
80	FURTHER extension
85	Metastasis
99	UNKNOWN if extension or metastasis

Note 1: Melanoma (M-8720-8790) of
scrotum only is included in the
melanoma scheme.

Note 2: Mycosis fungoides (M-9700)
or Sezary's disease (M-9701) of
scrotum only is included in the
mycosis fungoides scheme.

BODY OF PENIS, SCROTUM, AND OTHER MALE GENITAL ORGANS
(excl. Malignant Melanoma, Kaposi's Sarcoma, Mycosis
Fungoides, Sezary's Disease, and Other Lymphomas of Scrotum)
187.3, 187.5-187.9

LYMPH NODES

- 0 No lymph node involvement
- - - - -
- 1 REGIONAL Lymph Nodes
 - External iliac
 - Internal iliac (hypogastric)
 - Superficial inguinal
(femoral)
 - Deep inguinal: Rosenmuller's
or Cloquet's node
 - Regional lymph node(s), NOS
- - - - -
- DISTANT Lymph Nodes
- 7 Other than above
- - - - -
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

URINARY BLADDER, RENAL PELVIS and URETERS

DISTINGUISHING "IN SITU" AND "LOCALIZED" TUMORS FOR URINARY SITES

Careful attention must be given to the use of the term "confined to mucosa" for urinary bladder.

Historically, carcinomas described as "confined to mucosa" have been coded as localized. However, pathologists almost uniformly use this designation for non-invasive tumor as well. In order to provide greater specificity and to rule out the possibility of classifying noninvasive tumors in this category, abstractors should determine:

- 1) if the tumor is confined to the epithelium, in which case it is in situ, OR
- 2) if the tumor has penetrated the basement membrane to invade the lamina propria, in which case it is localized and is coded to invasion of the lamina propria. Only if this separation cannot be made should the tumor be coded to "confined to mucosa."

The mucosa of the urinary tract consists of:

The EPITHELIAL LAYER contains no blood vessels or lymphatics.

The BASEMENT MEMBRANE, a sheet of extracellular material, functions as a filtration barrier and a boundary involved in generating and maintaining tissue structure.

The LAMINA PROPRIA, composed of areolar connective tissue, contains blood vessels, nerves, and, in some regions, glands. Once tumor has broken through the basement membrane into the lamina propria, it can spread by way of the lymphatics and blood vessels to other parts of the body.

The urinary sites do NOT have a MUSCULARIS MUCOSAE, and, therefore, the lamina propria and the submucosa are difficult to separate. These terms are used interchangeably.

The SUBMUCOSA is a thick layer of either dense or areolar connective tissue. It contains blood vessels, lymphatic vessels, nerves, and, in some regions, glands.

The MUSCULARIS PROPRIA is composed of multiple layers of muscle tissue; it constitutes the wall of the organ.

URINARY BLADDER, RENAL PELVIS and URETERS

The SEROSA, the outermost layer covering, is a serous membrane, part of the visceral peritoneum. It covers only the superior surface of the urinary bladder. There is no serosa on the renal pelvis or ureters. Where there is no serosa, the connective tissue of surrounding structures merges with the connective tissue of the urinary organs and is called ADVENTITIA.

URINARY BLADDER, RENAL PELVIS and URETERS

PRIMARY SITE	MUCOSA			MUSCULARIS PROPRIA	SEROSA
	Epithelium	B A S E : M E M B R A N E :	Lamina Propria/ Submucosa		
Urinary Bladder (188.)	Yes		Yes	Yes	Yes, on superior surface
Renal pelvis (189.1)	Yes		Yes	Yes	No
Ureter(s) (189.2)	Yes		Yes	Yes	No

URINARY BLADDER
188.0-188.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; x-ray report (KUB); physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 Sessile carcinoma-IN SITU; Carcinoma-IN SITU, NOS
- 05 Noninvasive papillary (transitional) carcinoma
- 10 Confined to mucosa, NOS
- 15 Invasive tumor confined to: Subepithelial connective tissue (tunica propria, lamina propria, submucosa, stroma)
- Muscle (muscularis) invaded
- 20 NOS
- 21 Superficial muscle--inner half
- 22 Deep muscle--outer half
- 23 Extension through full thickness of bladder wall
- 30 Localized, NOS
- 40 Subserosal tissue
Perivesical fat
- 50 Extension to/through serosa (mesothelium); peritoneum
- 60 Prostate
Urethra, including prostatic urethra
Ureter
- 65 Vas deferens; seminal vesicle
Rectovesical/Denonvilliers' fascia
Parametrium
Uterus
Vagina

Note 1: The lamina propria and submucosa tend to merge when there is no muscularis mucosae, so these terms will be used interchangeably.

Note 2: The meaning of the terms "invasion of mucosa, grade 1" and "invasion of mucosa, grade 2" varies with the pathologist who must be queried to determine whether the carcinoma is "in situ" or "invasive."

Note 3:

If extension code is:	Behavior code must be:
00 or 05	2
10	2 or 3
15+	3

EXTENSION (cont'd)

- 70 Bladder FIXED
- 75 Pelvic wall
Abdominal wall
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or
metastasis

LYMPH NODES

- 0 No lymph node involvement
-
- REGIONAL Lymph Nodes (incl. contra-
lateral and bilateral)
- Perivesical
- Iliac: Internal (hypogastric):
- Obturator
- External
- Iliac, NOS
- Sacral (lateral, presacral,
sacral promontory (Gerota's),
or NOS)
- Pelvic, NOS
- Regional lymph node(s), NOS
- 1 Single lymph node \leq 2 cm
- 2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated
-
- DISTANT Lymph Nodes
- 6 Common iliac
- 7 Other than above
-
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

KIDNEY (Renal) PARENCHYMA
189.0

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU

10 Invasive cancer confined to kidney cortex and/or medulla

20 Renal pelvis or calyces involved
Invasion of renal capsule

30 Localized, NOS

40 Perirenal (perinephric) tissue/ fat
Renal (Gerota's) fascia
Adrenal gland, ipsilateral
Retroperitoneal soft tissue |

60 Extension to:
Blood vessels:
Extrarenal portion of renal vein; renal vein, NOS
Inferior vena cava
Tumor thrombus in a renal vein, NOS |

65 Extension beyond Gerota's fascia to:
Ureter, incl. implant(s), ipsilateral
Tail of pancreas
Ascending colon from right kidney
Descending colon from left kidney
Duodenum from right kidney
Peritoneum
Diaphragm

70 Ribs |

75 Spleen |
Liver
Stomach

80 FURTHER extension

85 Metastasis

99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. contra-
lateral and bilateral)

Renal hilar
Paracaval
Aortic (para-, peri-, lateral)
Retroperitoneal, NOS
Regional lymph node(s), NOS

1 Single lymph node \leq 2 cm

2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm

3 Lymph node(s), at least one >5 cm

5 Size not stated

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

**RENAL (Kidney) PELVIS, URETER,
AND URINARY SYSTEM, NOS**
189.1-189.2, 189.8-189.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	mm	cm
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 Carcinoma-IN SITU, NOS
- 05 Papillary noninvasive carcinoma
- 10 Subepithelial connective tissue (lamina propria, submucosa) invaded
- 20 Muscularis invaded
- 30 Localized, NOS
- 40 Extension to adjacent (connective) tissue:
Peripelvic/periureteric tissue
Retroperitoneal soft/connective tissue
- 60 Kidney parenchyma and kidney, NOS, from renal pelvis
Ureter from renal pelvis
- 65 Extension to bladder from distal ureter
Implants in distal ureter
- 66 Extension to major blood vessel(s):
Aorta, renal artery/vein, vena cava (inferior)
Tumor thrombus in a renal vein, NOS
- 70 Perinephric fat via kidney
Spleen
Pancreas
Liver
Ascending colon from right renal pelvis/ureter
Descending colon from left renal pelvis/ureter
Colon, NOS
Kidney parenchyma from other than renal pelvis
Bladder, other than from distal ureter, i.e., renal pelvis

Note:

If extension code is:	Behavior code must be:
00 or 05	2
10+	3

RENAL (Kidney) PELVIS, URETER,
AND URINARY SYSTEM, NOS
189.1-189.2, 189.8-189.9

EXTENSION (cont'd)

- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes (incl. contra-
lateral and bilateral)

Renal Pelvis:

- Renal hilar
- Paracaval
- Aortic (para-, peri-, lateral)
- Retroperitoneal, NOS
- Regional lymph node(s), NOS

Ureter:

- Renal hilar
- Iliac: Common
 - Internal (hypogastric)
 - External
- Paracaval
- Periureteral
- Pelvic, NOS
- Regional lymph node(s), NOS

1 Single lymph node \leq 2 cm

2 Single lymph node >2-5 cm OR
multiple nodes, none
greater than 5 cm

3 Lymph node(s), at least one >5 cm

5 Size not stated

DISTANT Lymph Nodes

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

URETHRA AND PARAURETHRAL GLAND
189.3-189.4

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; endoscopic examination; radiographic report--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 Carcinoma-IN SITU, NOS
- 05 Noninvasive papillary, polypoid, or verrucous carcinoma
- 10 Subepithelial connective tissue (lamina propria, submucosa) invaded
- 20 Muscularis invaded |
- 30 Localized, NOS
- 40 Periurethral muscle (sphincter) |
Corpus spongiosum
Prostate
- 60 Corpus cavernosum |
Vagina
Bladder neck
Seminal vesicle(s)
- 70 Other adjacent organs |
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

Note:

If extension code is:	Behavior code must be:
00 or 05	2
10+	3

URETHRA AND PARAURETHRAL GLAND
189.3-189.4

LYMPH NODES

- 0 No lymph node involvement

REGIONAL Lymph Nodes (incl. contra-
lateral and bilateral)
- Iliac: Common
 - Internal (hypogastric):
 - Obturator
 - External
 - Inguinal (superficial or deep)
 - Presacral, sacral NOS
 - Pelvic, NOS
 - Regional lymph node(s), NOS
- 1 Single lymph node ≤ 2 cm
- 2 Single lymph node $>2-5$ cm OR
multiple nodes, none
greater than 5 cm
- 3 Lymph node(s), at least one >5 cm
- 5 Size not stated

DISTANT Lymph Nodes
- 7 Other than above

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

EYE AND LACRIMAL GLAND
190.0-190.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU
- 10 Tumor confined to site of origin:
 - Iris
 - Ciliary body
 - Choroid
 - Retina
 - Lacrimal gland
 - Cornea
 - Conjunctiva
 - Soft tissue of orbit (sarcomas)
- 20 Intraocular extension
- 30 Localized, NOS
- 40 Extraocular extension (excl. conjunctiva):
 - Paranasal sinuses
 - Cranium/skull
 - Eyelid
 - Optic nerve
 - Invading orbit--conjunctiva
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

- 0 No lymph node involvement

- 1 REGIONAL Lymph Nodes
 - Submandibular nodes
 - Parotid (preauricular) nodes
 - Upper cervical
 - Regional lymph node(s), NOS-----
- 7 DISTANT Lymph Nodes

- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

BRAIN AND CEREBRAL MENINGES
191.0-191.9, 192.1

SIZE OF PRIMARY TUMOR

(from pathology report;
operative report; radiographic
report--in priority order.)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU
- 10 Supratentorial tumor confined to **CEREBRAL HEMISPHERE** (cerebrum) on one side:
 - Frontal lobe
 - Temporal lobe
 - Parietal lobe
 - Occipital lobe
- 11 Infratentorial tumor confined to **CEREBELLUM** on one side:
 - Vermis: Median lobe of cerebellum
 - Lateral lobes
- 12 Infratentorial tumor confined to **BRAIN STEM** on one side:
 - Thalamus, hypothalamus
 - Midbrain (mesencephalon)
 - Pons
 - Medulla oblongata
- 20 Infratentorial tumor: **Both cerebellum and brain stem** involved WITH tumor on one side
- 30 Confined to ventricles or tumor invades or encroaches upon ventricular system
- 40 Tumor crosses the midline, involves corpus callosum (incl. splenium), or contralateral hemisphere
- 50 Supratentorial tumor extends infratentorially to involve cerebellum or brain stem
- 51 Infratentorial tumor extends supratentorially to involve cerebrum (cerebral hemisphere)
- 60 Tumor invades:
 - Bone (skull)
 - Meninges (dura)
 - Major blood vessel(s)
 - Nerves--cranial nerves; spinal cord/canal

EXTENSION (cont'd)

- 70 Extension to:
Nasopharynx
Posterior pharynx
Nasal cavity
Outside central nervous
system (CNS)
Circulating cells in cerebral
spinal fluid (CSF)
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension
or metastasis

LYMPH NODES

- 9 Not Applicable

OTHER PARTS OF NERVOUS SYSTEM
 192.0, 192.2-192.3, 192.8-192.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 10 Tumor confined to tissue or site of origin
- 30 Localized, NOS
- 40 Meningeal tumor infiltrates nerve
Nerve tumor infiltrates meninges (dura)
- 50 Adjacent connective/soft tissue |
Adjacent muscle
- 60 Major blood vessel(s) |
Sphenoid and frontal sinuses (skull)
Brain, for cranial nerve tumors |
- 70 Brain, except for cranial |
nerve tumors
Eye
Bone, other than skull
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

OTHER PARTS OF NERVOUS SYSTEM
192.0, 192.2-192.3, 192.8-192.9

LYMPH NODES

9 Not Applicable

THYROID GLAND
193.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; radiographic report; physical examination--in priority order)

000 No mass; no tumor found
001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

- 00 IN SITU: Noninvasive
- 10 Single invasive tumor confined to thyroid
- 20 Multiple foci confined to thyroid
- 30 Localized, NOS
- 40 Into thyroid capsule, but not beyond
- 50 Pericapsular soft/connective tissue |
Parathyroid
Strap muscle(s): Sternothyroid, omohyoid, sternohyoid
Nerves: Recurrent laryngeal, vagus
- 60 Extension to:
Major blood vessel(s): Carotid artery, thyroid artery or vein, jugular vein
Sternocleidomastoid muscle
Esophagus
Larynx, incl. thyroid and cricoid cartilages
Tumor is described as "FIXED to adjacent tissues"
- 70 Trachea |
Skeletal muscle, other than strap or sternocleidomastoid muscle |
Bone
- 80 FURTHER extension
- 85 Metastasis
- 99 UNKNOWN if extension or metastasis

LYMPH NODES

0 No lymph node involvement

REGIONAL Lymph Nodes

Delphian node
Anterior cervical:
 prelaryngeal, laterotracheal,
 pretracheal (recurrent laryngeal
 nerve chain)
Internal jugular (upper and
 lower deep cervical):
 jugulodigastric
 jugulo-omohyoid
Retropharyngeal
Cervical, NOS

1 Ipsilateral cervical nodes
2 Bilateral, contralateral, or
 midline cervical nodes

3 Mediastinal nodes

5 Regional lymph node(s), NOS

DISTANT Lymph Nodes

6 Submandibular (submaxillary)
 Submental

7 Other than above

8 Lymph Nodes, NOS

9 UNKNOWN; not stated

THYMUS AND OTHER ENDOCRINE GLANDS
 164.0, 194.0-194.1, 194.3-194.6, 194.8-194.9

SIZE OF PRIMARY TUMOR

(from pathology report; operative report; physical examination--in priority order)

000 No mass; no tumor found
 001 Microscopic focus or foci only

	<u>mm</u>	<u>cm</u>
002	≤2	≤0.2
003	3	0.3
...		
...		
009	9	0.9
010	10	1.0
...		
...		
099	99	9.9
100	100	10.0
...		
...		
990	990+	99.0+
999	Not stated	

EXTENSION

00 IN SITU: Noninvasive
 10 Invasive carcinoma confined to gland of origin
 30 Localized, NOS
 40 Adjacent connective tissue |
 60 Adjacent organs/structures |
 80 FURTHER extension
 85 Metastasis
 99 UNKNOWN if extension or metastasis

THYMUS AND OTHER ENDOCRINE GLANDS
164.0, 194.0-194.1, 194.3-194.6, 194.8-194.9

LYMPH NODES

- 0 No lymph node involvement
- - - - -
- 1 REGIONAL Lymph Nodes
- - - - -
- 7 DISTANT Lymph Nodes
- - - - -
- 8 Lymph Nodes, NOS
- 9 UNKNOWN; not stated

KAPOSI'S SARCOMA OF ALL SITES |
 (M-9140)

ASSOCIATED WITH HTLV-4 (AIDS) |

001 Yes
 002 No
 999 Unknown

EXTENSION

SINGLE LESION

- 11 Skin
- 12 Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva) |
- 13 Visceral (e.g., pulmonary, gastrointestinal tract, spleen, other) |

MULTIPLE LESIONS

- 21 Skin
- 22 Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva)
- 23 Visceral (e.g., pulmonary, gastrointestinal tract, spleen, other) |
- 24 (21) plus (22)
- 25 (21) plus (23)
- 26 (22) plus (23)
- 27 (21) plus (22) plus (23)
- 29 Multiple lesions, NOS
- 99 UNKNOWN; not stated

LYMPH NODES

0 No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement) |

REGIONAL Lymph Nodes

1 Clinically enlarged palpable regional lymph node(s) (adenopathy), and either pathologically negative regional nodes or no pathological statement |

2 No clinically enlarged palpable regional lymph nodes(s) (adenopathy); pathologically positive regional lymph node(s)

3 Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive regional lymph nodes

7 DISTANT Lymph Nodes |

8 Lymph Nodes, NOS |

9 UNKNOWN; not stated

HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES
(excl. Mycosis Fungoides and Sezary's Disease)
(M-9590-9594, 9650-9698, 9702-9704)

SIZE OF PRIMARY TUMOR

999 Not applicable

Note 1: E = Extralymphatic means other than lymph nodes and other lymphatic structures.

These lymphatic structures include spleen, thymus gland, Waldeyer's ring (tonsils), Peyer's patches (ileum) and lymphoid nodules in the appendix.

Any lymphatic structure is to be coded the same as a lymph node region.

Note 2: S = Spleen involvement

Note 3: If there is no mention of extranodal involvement but several diagnostic procedures were done, including laparotomy, interpret as no involvement.

Note 4: Involvement of adjacent soft tissue does not alter the classification.

EXTENSION

- 10 Involvement of a single lymph node region
Stage I
- 11 Localized involvement of a single extralymphatic organ or site
Stage IE
- 20 Involvement of two or more lymph node regions on the same side of the diaphragm
Stage II
- 21 Localized involvement of a single extralymphatic organ or site and its associated regional lymph node(s) on the same side of the diaphragm
Stage IIE
- 30 Involvement of lymph node regions on both sides of the diaphragm
Stage III
- 31 (30) plus localized involvement of an associated extralymphatic organ or site
Stage IIIIE
- 32 (30) plus involvement of the spleen
Stage IIIS
- 33 (31) + (32)
Stage IIIIES
- 80 Disseminated (multifocal) involvement of one or more extralymphatic organ(s)
Stage IV
- 99 UNSTAGED; not stated

**HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA OF ALL SITES
(excl. Mycosis Fungoides and Sezary's Disease)
(M-9590-9594, 9650-9698, 9702-9704)**

SYSTEMIC SYMPTOMS AT DIAGNOSIS

0 No B symptoms (Asymptomatic)

- - - - -

1 Any B symptom:

Night sweats

Unexplained fever (above 38° C)

Unexplained weight loss (gen-

erally >10% loss of body

weight in the six months

before admission)

B symptoms, NOS

2 Pruritus (if recurrent and
unexplained)

3 1 plus 2

- - - - -

9 UNKNOWN if symptoms; insufficient
information

**HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE,
and MYELOPROLIFERATIVE NEOPLASMS**
(M-9720, 9722-9723, 9730-9731, 9760-9764, 9800-9940, 9950-9980)

SIZE OF PRIMARY TUMOR

EXTENSION

999 Not applicable

10 Localized disease: **Solitary
plasmacytoma only**

80 Systemic Disease: All others

This scheme includes the following:

- 9720 = Malignant histiocytosis
Histiocytic medullary reticulosis
- 9722 = Letterer-Siwe's disease
- 9723 = True histiocytic lymphoma
- 9730 = Multiple myeloma
Myeloma, NOS
Myelomatosis
- 9731 = Plasmacytoma, NOS
Extramedullary plasmacytoma
Solitary myeloma/plasmacytoma
- 9760 = Immunoproliferative disease, NOS
- 9761 = Waldenstrom's macroglobulinemia
- 9762 = Gamma heavy chain disease
Franklin's disease
- 9763 = Immunoproliferative small intestinal disease
- 9764 = Malignant monoclonal gammopathy
- 9800 = Leukemia, NOS
- 9801 = Acute leukemia, NOS
Blast cell leukemia
Undifferentiated leukemia
- 9802 = Subacute leukemia, NOS
- 9803 = Chronic leukemia, NOS
- 9804 = Aleukemic leukemia, NOS
- 9820 = Lymphoid Leukemia, NOS
Lymphocytic leukemia, NOS
- 9821 = Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute lymphoid leukemia
Acute lymphatic leukemia
- 9822 = Subacute lymphoid leukemia
- 9823 = Chronic lymphocytic leukemia
- 9824 = Aleukemic lymphoid leukemia
- 9825 = Prolymphocytic leukemia
- 9830 = Plasma cell leukemia
Plasmacytic leukemia

**HEMATOPOIETIC, RETICULOENDOTHELIAL, IMMUNOPROLIFERATIVE,
AND MYELOPROLIFERATIVE NEOPLASMS
(M-9720, 9722-9723, 9730-9731, 9760-9764, 9800-9940, 9950-9980)**

LYMPH NODES

9 Not applicable

- 9840 = Erythroleukemia
Erythremic myelosis, NOS
- 9841 = Acute erythremia
Di Guglielmo's disease
Acute erythremic myelosis
- 9842 = Chronic erythremia
- 9850 = Lymphosarcoma cell leukemia
- 9860 = Myeloid leukemia, NOS
Granulocytic leukemia
Myelomonocytic leukemia, NOS
- 9861 = Acute myeloid leukemia
Acute myeloblastic leukemia
Acute granulocytic leukemia
Acute myelocytic leukemia
- 9862 = Subacute myeloid leukemia
- 9863 = Chronic myeloid leukemia
- 9864 = Aleukemic myeloid leukemia
- 9866 = Acute promyelocytic leukemia
- 9867 = Acute myelomonocytic leukemia
- 9868 = Chronic myelomonocytic leukemia
- 9870 = Basophilic Leukemia
- 9880 = Eosinophilic Leukemia
- 9890 = Monocytic Leukemia, NOS
- 9891 = Acute monocytic leukemia
Acute monoblastic leukemia
Monoblastic leukemia, NOS
- 9892 = Subacute monocytic leukemia
- 9893 = Chronic monocytic leukemia
- 9894 = Aleukemic monocytic leukemia
- 9900 = Mast cell leukemia
- 9910 = Acute megakaryoblastic leukemia
Megakaryocytic leukemia
- 9930 = Myeloid sarcoma
Granulocytic sarcoma
Chloroma
- 9931 = Acute panmyelosis
- 9932 = Acute myelofibrosis
- 9940 = Hairy cell leukemia
Leukemic reticuloendotheliosis
- 9950 = Malignant polycythemia (rubra) vera
- 9960 = Malignant myeloproliferative disease, NOS
- 9961 = Malignant myelosclerosis with myeloid metaplasia
- 9962 = Malignant idiopathic/essential (hemorrhagic) thrombocytopenia
- 9970 = Malignant lymphoproliferative disease, NOS
- 9980 = Malignant myelodysplastic syndrome

UNKNOWN AND ILL-DEFINED PRIMARY SITES

199.9, 195.0-195.5, 195.8

169._ and 196._, Other than hematopoietic, reticuloendothelial,
immunoproliferative and myeloproliferative neoplasms,
Hodgkin's disease and non-Hodgkin's lymphoma, and
Kaposi's sarcoma

SIZE OF PRIMARY TUMOR

999 Not applicable

EXTENSION

99 Not Applicable

UNKNOWN AND ILL-DEFINED PRIMARY SITES

199.9, 195.0-195.5, 195.8

169._ and 196._, Other than hematopoietic, reticuloendothelial,
immunoproliferative and myeloproliferative neoplasms,
Hodgkin's disease and non-Hodgkin's lymphoma, and
Kaposi's sarcoma

LYMPH NODES

9 Not Applicable

INDEX

Abdomen, Ill-defined sites, 3, 150
Accessory (paranasal) sinuses, 74
Acute (differentiated) progressive histiocytosis, 148
Acute leukemia
 Lymphatic, lymphoblastic, lymphocytic, lymphoid, 148
Acute myelomonocytic leukemia, 148
Adnexa, definition, 104
Adrenal gland, 142
Alimentary tract, 68
Ambiguous term
 Compatible with, 1
 Consistent with, 1
 Equivocal, 1
 Induration, 1, 98
 Possible, 1
 Probable, 1
 Questionable, 1
 Suggests, 1
 Suspected, 1
 Suspicious, 1
 To, into, onto, encroaching, 1
Ampulla of Vater, 60
Anal canal, 52
Anorectum and anorectal junction, 52
Anus, NOS, 52
Aortic body and other paraganglia, 142
Appendix, 48
Aryepiglottic fold, 36
Ascites
 Status of capsule code, 106
 With malignant cells
 FIGO stage, 106
 Without malignant cells
 FIGO stage, 106

Back, Ill-defined sites, 3, 150
Bartholin's gland, 112
Basement membrane, 10, 40, 41, 103, 124, 125
Bile ducts, 54
 Extrahepatic, 58
 Intrahepatic, 54
Biliary tract, Other and NOS, 56
Biopsy, code size of excisional, 3
Bladder (See urinary bladder.), 124, 125, 126
Blast cell leukemia, 148
Blood, 148
Body of
 Pancreas, 62
 Penis, 122
 Stomach, 44

- Bone, 88
 - Marrow, 148
 - Pelvic, sacrum, and coccyx, 88
 - Rib, sternum, and clavicle, 88
 - Scapula, 88
 - Short and long
 - Upper and lower limbs, 88
 - Shoulder, 88
 - Skull and face, 88
- Brain, 136
 - Other parts of, 136
 - Stem, 136
- Brain tumors, 5
- Breast, 98
 - Axillary tail, 98
 - Diffuse tumor, 3, 98
 - Female, 98
 - Male, 98
 - Nipple, 98
 - Quadrants, central, inner and outer, 98
- Broad ligament(s), 108
- Bronchogenic, 80
- Bronchopneumonia, 80
- Bronchus, main stem, 80
- Buccal mucosa, 24
 - Head and neck, invasive and noninvasive, 11
- Burkitt's lymphoma, 146

- Cardia of stomach, 44
- Carina, 80
- Carotid body, 142
- Cartilage, articular, 88
- Cecum, 48
- Cerebellum, 136
- Cerebral meninges, 136
- Cerebrum, 136
- Cervical esophagus, 42
- Cervical stump, 100
- Cervix uteri, 100
 - Other parts, 100
- Cheek (buccal) mucosa, 24
- Choroid, 134
- Ciliary body, 134
- Circulating cells in peripheral blood, 96
- Circumference, entire, 3
- Clinical information, 1
- Clitoris, 112
- Cloacogenic zone, 52
- Colon
 - Appendix, 48
 - Ascending, 48
 - Cecum, 48
 - Colon, NOS, 48
 - Descending, 48
 - Flexures, 48
 - Invasive and noninvasive, 40, 41
 - Sigmoid, 48
 - Transverse, 48

Colorectal, multiple polyposis, 3, 48, 50
 Columnar epithelium, 103
 Commissure of lip, 12
 Confined to the
 Endometrium (mucosa)
 Corpus uteri, 103
 Epithelium, 40, 41, 124
 Columnar, 103
 Head and neck, 10
 Mucosa
 Digestive system, 40, 41
 Head and neck, 10
 Renal pelvis (kidney), 124
 Ureters, 124
 Urinary bladder, 124
 Conjunctiva of eye, 134
 Connective tissue, 90
 Cooper's ligament(s), 98
 Cornea, 134
 Corpus uteri, 103, 104
 Invasive and noninvasive, 103
 Cowper's gland, 132
 Cranial nerve, 138
 Cul de sac, 66
 Curvatures of stomach
 Lesser and greater, 44
 Cyst, code size of tumor, 3

 Death certificate ONLY Codes, 7
 Definition of EOD, 1
 Definitive therapy, 1
 Di Gugliemo's disease, 148
 Diffuse, 3
 Digestive system, 40, 41, 68
 Ill-defined sites, 3, 68
 Dimpling of skin of breast, 98
 Duodenum, 46

 Endocervix, 100
 Endocrine glands, 142
 Endometrium, 103, 104
 Epididymis, 122
 Epiglottis
 Anterior surface, 32
 Lingual (anterior) surface
 AJCC definition, 32
 Epithelial layer, 40, 41, 124, 125
 Head and neck, 10
 Equivalences in units of mm, cm, in, 4
 Erythremia, acute, chronic, 148
 Erythremic myelosis, acute, NOS, 148
 Erythroleukemia, 148
 Esophagus, 42
 Abdominal, 42
 Anatomic limits, 42
 Cervical, 42

- Esophagus (cont'd)
 - Intrathoracic (upper, mid, lower), 42
 - Invasive and noninvasive, 40, 41
 - Lower 1/3, 42
 - Middle 1/3, 42
 - Thoracic, 42
 - Tumor entire circumference, 3
- Ethmoid sinus, 74
- Exocervix, 100
- Exploratory/definitive surgery
 - Lymph node, 104
- Extent of disease, 1
 - Autopsy ONLY cases, 1
 - Death certificate ONLY, 1, 7
 - Definition, 5
 - Definitive surgery after
 - Excisional Bx, 3
 - Extension, 5
 - Adjacent organs, 5
 - General instructions, 1
 - Ignore metastasis after diagnosis, 1
 - Limitations, 1
 - Lymph nodes, 5
 - Metastasis to distant sites, 5
 - Size, 3
 - Equivalences in mm, cm, in, 4
 - Surgical cases pretreated by radiation, 1
 - System identification, 1
 - Time limit for EOD, 1
 - Within organ, 5
- External Ear
 - Skin of, 92
- Extrahepatic bile ducts, 58
- Extramedullary plasmacytoma, 148
- Extranodal sites, lymphoma, 146
- Extremities
 - Skin of arms, shoulder, etc., 92
- Extremities, ill-defined sites, 150
- Eye, 134
 - Orbit, NOS, 134
- Eyeball, 134
- Eyelid
 - Skin of, 92
- Face
 - Skin and other unspecified parts, 92
- Face, ill-defined sites, 150
- Fallopian tube, 108
- Familial/multiple polyposis, 3, 48, 50
- Federation of Gynecology and Obstetrics (See FIGO stage.), 100
- Female
 - Genital organs, 114
 - Genitourinary tract, 114
- FIGO stage, 100, 104, 106, 110, 112
 - Ascites with malignant cells, 106
 - Ascites without malignant cells, 106

Flank
 Ill-defined sites, 150
 Floor of mouth, 22
 Invasive and noninvasive, 11
 Fornix of vagina, 110
 Franklin's disease, 148
 Frontal lobe of brain, 136
 Frontal sinus, 74
 Fundus of
 Stomach, 44
 Uterus, 104

 Gallbladder, 56
 Gamma heavy chain disease, 148
 Gartner's duct, 110
 Gastrointestinal tract, 68
 Genital tract, female, 114
 Gingiva (See gum.), 20
 Gland
 Adrenal, 142
 Endocrine, 142
 Major salivary, 18
 Parathyroid, 142
 Parotid, 18
 Pineal, 142
 Submandibular, 18
 Suprarenal, 142
 Thymus, 142
 Thyroid, 140
 Gland, Sublingual, 18
 Glans penis, 120
 Glottis including supra- and subglottis, 76
 Gum (gingiva), 20
 Invasive and noninvasive, 10, 11
 Lower, 20
 Upper, 20

 Hairy cell leukemia, 148
 Hard palate, 26
 Invasive and noninvasive, 10, 11
 Head and neck, 10, 11
 Ill-defined sites, 150
 Heart, 84
 Hematopoietic system, 148
 Size not applicable, 3
 Hepatic flexure, 48
 Colon, 48
 Histiocytic medullary reticulosis, 148
 Histiocytic, (true) lymphoma, 146
 Hodgkin's disease, 8, 146
 Homolateral vs ipsilateral, 6, 8
 Hymen, 110
 Hypopharynx (laryngopharynx), 36
 Anatomic limits, 36
 Posterior wall of, 36

Ileocecal valve and junction, 48
 Ill-defined
 Abdomen, 150
 Head and neck, 150
 Thorax, 150
 Ill-defined digestive and peritoneal sites, 3, 68
 Ill-defined primary sites
 Back, 150
 Diseases, 7
 Flank, 150
 Intestinal tract, 68
 Intrathoracic organs, 86
 Limbs, upper and lower, 150
 Lip, 38
 Oral Cavity, 38
 Pelvis, 150
 Peritoneum, 68
 Pharynx, 38
 Respiratory system, 66
 Trunk, 150
 Unknown primary site, 150
 Ill-defined respiratory/intrathoracic organs, 3, 86
 Immunoproliferative Disease, 148
 Immunoproliferative small intestinal disease, 148
 Instructions for using EOD, 1
 Intestinal tract, 68
 Intrahepatic bile duct, 54
 Intrathoracic
 Esophagus, 42
 Intrathoracic organs
 Ill-defined sites, 3, 86
 Iris, 134
 Islets of Langerhans, 62
 Isthmus uteri, 104

 Jejunum, 46
 Joints, 88

 Kaposi's sarcoma, 144
 Kidney, 128
 Parenchyma, (renal), 128
 Renal pelvis (kidney), 130

 Labia majora
 Skin, malignant melanoma, 94
 Labial mucosa
 AJCC definition, 12
 Mucosa of
 AJCC definition, 24
 Labium majus and minus, 112
 Lacrimal gland and duct, 134
 Lamina propria
 Digestive system, 40, 41
 Head and neck, 10
 Renal pelvis (kidney), 124, 125
 Ureters, 124, 125
 Urinary bladder, 124, 125

Laryngeal cartilage, 76
 Laryngopharynx, 36
 Larynx, 76
 Lennert's lymphoma, 146
 Letterer-Siwe's disease, 8, 148
 Leukemia
 Acute megakaryoblastic (megakaryocytic), 148
 Acute, chronic, subacute, aleukemic, 148
 Basophilic, 148
 Blast cell, 148
 Coding, 8
 Eosinophilic, 148
 Granulocytic, myeloblastic, myelocytic, myeloid, 148
 Hairy cell, 148
 Lymphosarcoma cell, 148
 Mast cell, 148
 Monocytic, monoblastic, megakaryocytic, 148
 Myeloid, granulocytic, myeloblastic, 148
 NOS, 148
 Plasma cell, plasmacytic, prolymphocytic, 148
 Promyelocytic
 Myelomonocytic, 148
 Size not applicable, 3
 Undifferentiated, 148
 Leukemic reticuloendotheliosis, 148
 Lingual tonsil, 14
 Linitis plastica, 3
 Lip, 12
 Commissure, 12
 Ill-defined sites, 38
 Invasive and noninvasive, 11
 Lower, 12
 Mucosa
 Head and neck, 12
 Upper, 12
 Liver, 54
 Lobe of lung, entire, 3
 Lower esophagus, 42
 Lung
 Diffuse tumor, 3
 Other parts, 80
 Upper, middle and lower lobes, 80
 Lymph nodes
 Chest x-ray with no mention of, 5
 Enlarged, 5
 Exploratory/definitive surgery, 104
 First station, 5
 Fixed, 5
 Homolateral, 6, 8
 In situ
 Code, 5
 Inaccessible, 5, 6
 Involved
 Coding, 5
 Ipsilateral, 6, 8
 Localized, NOS, 5
 Matted, 5

- Lymph nodes (cont'd)
 - Mediastinal mass, 5
 - Mesentery, 5
 - Non-palpable, 5
 - NOS, 5
 - Palpable, 5
 - Pathology review of regional, 5
 - Positive, number examined, 5
 - Regional, NOS, 6, 8
 - Retroperitoneal mass, 5
 - Shotty, 5
 - Small bilateral nodes, 5
 - Unknown involvement
 - Code, 5
 - Visible swelling, 5
- Lymph nodes and lymphoid tissue, 146
 - Coding, 5
- Lymphoepithelial lymphoma, 146
- Lymphoma
 - All sites, 146
 - Burkitt's, 146
 - Extranodal, 8
 - Extranodal sites, 146
 - Hodgkin's disease, 146
 - Lymph nodes
 - Enlarged, 5
 - Visible swelling, 5
 - Nodal, 8
 - Non-Hodgkin's, 146
 - Size not applicable, 3
 - True histiocytic, 146
- Lymphoproliferative disease, NOS, 148
- Lymphosarcoma cell leukemia, 148
- Lymphosarcoma, NOS, 146

- Main stem bronchus, 80
- Major salivary gland, 18
- Male genital organs, 122
- Malignant histiocytosis, 148
- Malignant idiopathic/essential (hemorrhagic) thrombocytopenia, 148
- Malignant lymphoma, 146
- Malignant lymphoproliferative disease, NOS, 148
- Malignant melanoma, 94
- Malignant monoclonal gammopathy, 148
- Malignant myelodysplastic syndrome, 148
- Malignant myeloproliferative disease, NOS, 148
- Malignant myelosclerosis with myeloid metaplasia, 148
- Malignant polycythemia (ruba) vera, 148
- Mandible, 88
- Maxillary sinus, 72
- Mediastinal mass, 80
- Mediastinum, anterior and posterior, 84
- Melanoma
 - Malignant, 94
 - Thickness of tumor instead of size, 3
- Meninges
 - Cerebral, 136

Mesentery, 66
 Mesoappendix, 66
 Middle Ear, 70
 Middle Esophagus, 42
 Mouth, 22
 Anterior floor, 22
 Floor of, 22
 Lateral floor, 22
 Other parts, 30
 Palate, 30
 Roof, 30
 Vestibule, 24
 Mucosa, head and neck, 11
 Multiple myeloma, 148
 Coding, 8
 Muscularis mucosae
 Digestive system, 41
 Muscularis mucosae, 40, 41
 Head and neck, 10, 11
 Muscularis propria
 Digestive system, 40, 41
 Head and neck, 10, 11
 Renal pelvis (kidney), 124, 125
 Ureters, 124, 125
 Urinary bladder, 124, 125
 Mycosis fungoides, 8, 96
 Size not applicable, 3
 Myelofibrosis, acute, 148
 Myeloma, NOS, 148
 Myelomatosis, 148
 Myeloproliferative disease
 Size not applicable, 3
 Myometrium, 103, 104

 Nasal cavity, 70
 Nasopharynx, 34
 Anatomic limits, 34
 Anterior, lateral, posterior and superior walls, 34
 Nerve, 138
 Cranial, 138
 Optic, 138
 Nervous system, 138
 Meninges, 138
 Other than brain, 138
 Spinal cord, 138
 Nipple retraction of breast, 98
 Non-Hodgkin's lymphoma, 8, 146
 Non-lipid reticuloendotheliosis, 148
 Noninvasive tumor, 5
 Corpus uteri, 103
 Digestive system, 40, 41
 Head and neck, 10
 Renal pelvis (kidney), 124, 125
 Ureters, 124, 125
 Urinary bladder, 124, 125
 Nonpolyp, 48

Obstructive pneumonitis, 80
 Occipital lobe of brain, 136
 Omentum, 66
 Oper/path information, 1
 Oral cavity, 30
 Ill-defined sites, 38
 Oropharynx, 32
 Anatomic limits, 32
 Anterior, posterior and lateral walls, 32
 Branchial cleft, 32
 Junctional region, 32
 Superior wall
 AJCC definition, 32
 Ovary, 106
 Ascites
 Status of capsule code, 3, 106
 Size, two digit code, 3, 106

 Palate, 26, 28
 Hard, 26
 Junction of hard and soft, 30
 Soft, 28
 Palpable lymph nodes, 5
 Pancreas, 62, 64
 Body of, 62
 Head of, 62
 Tail of, 62
 Unspecified, 64
 Pancreatic duct, 62
 Panmyelosis, acute, 148
 Parametrium, 108
 Paranasal sinuses, 74
 Parathyroid, 142
 Paraurethral gland, 132
 Parietal lobe of brain, 136
 Parotid gland, 18
 Pathology report, priority, 1
 Pathology review of regional lymph nodes, 5
 Pelvis, Ill-defined sites, 150
 Penis, 120
 Body of, 122
 Glans, 120
 Skin of, 120
 Malignant melanoma, 94, 120
 Peritoneum, 66
 Ill-defined sites, 3, 68
 Pharynx, 38
 Ill-defined sites, 38
 Pineal gland, 142
 Pituitary gland, 142
 Placenta, 104
 Plasma cell leukemia, 148
 Plasma cell tumors, 148
 Plasmacytoma, NOS, 148
 Pleura, parietal and visceral, 82
 Polyp (adenoma), 48
 Polyp, code size of tumor, 3

Polyposis, familial/multiple, 3
 Positive/excised regional lymph node coding, 5
 Postcricoid area, 36
 Posterior hypopharyngeal wall, 36
 Pouch of Douglas, 66
 Prepuce, 120
 Primary site, tumor overlaps boundaries of two or more, 5
 Polymphocytic leukemia, 148
 Prostate, 116
 Pylorus including antrum, 44
 Pyriform sinus, 36

 Radiation pretreatment for surgical patients, 1
 Rectosigmoid, 50
 Invasive and noninvasive, 41
 Junction, 50
 Rectouterine pouch, 66
 Rectum, 50
 Invasive and noninvasive, 40, 41
 Other parts of, 52
 Regional nodes, number of positive and examined, 7
 Renal pelvis (kidney), 124, 125, 130
 Invasive and noninvasive, 124, 125
 Respiratory system
 Ill-defined sites, 3, 86
 Upper tract, 86
 Reticuloendothelial system, 148
 Size not applicable, 3
 Reticuloendotheliosis, 8
 Retina, 134
 Retromolar area and trigone, 20
 Retroperitoneum, 66
 Rosenmuller's fossa (pharyngeal recess), 34
 Round ligament(s), 108

 Salivary gland, major, 18
 Sarcoma, myeloid/granulocytic (chloroma), 148
 Scalp and neck
 Skin of, 92
 Scrotum, 122
 Skin, malignant melanoma, 94, 122
 Seminal vesicle(s), 122
 Serosa
 Corpus uteri, 103
 Digestive system, 40, 41
 Renal pelvis (kidney), 124, 125
 Ureters, 124, 125
 Urinary bladder, 124, 125
 Sezary's cells, 96
 Sezary's disease, 8
 Sezary's syndrome, 96
 Sigmoid colon, 48
 Skin, 92
 Integumentary system, 92
 Malignant melanoma, 94
 Melanotic tumors, 94
 Mycosis fungoides, 96

- Skin (cont'd)
 - Nonmelanotic tumors, 92
 - Sezary's disease, 96
- Small intestine, 46
 - Invasive and noninvasive, 40, 41
- Soft palate, 28
 - AJCC definition, 28, 32
 - Inferior surface
 - AJCC definition, 32
 - Invasive and noninvasive, 11
- Soft tissue, 90
 - Head, face and neck, 90
 - Orbit of eye, 134
 - Pelvis and trunk, 90
 - Shoulder and hip, 90
 - Thorax and abdomen, 90
 - Upper and lower limbs, 90
- Solitary myeloma, 148
- Solitary plasmacytoma, 148
- Spermatic cord, 122
- Sphenoid sinus, 74
- Spinal cord, 138
- Spinal meninges, 138
- Splenic flexure of colon, 48
- Squamocolumnar junction of cervix, 100
- Stomach, 44
 - Anterior and posterior walls, 44
 - Diffuse tumor, 3
 - Invasive and noninvasive, 40, 41
- Stroma (lamina propria)
 - Corpus uteri, 103
- Subcutaneous tissue, 90
- Sublingual gland, 18
- Submandibular gland, 18
- Submucosa
 - Digestive system, 40, 41
 - Head and neck, 10, 11
 - Renal pelvis (kidney), 124, 125
 - Ureters, 124, 125
 - Urinary bladder, 124, 125
- Suprarenal gland, 142
- Surgery
 - Exploratory/definitive, 104
- Surgical observations, 1
- Systemic disease, 8

- T-cell lymphoma, 146
- T-zone lymphoma, 146
- Temporal lobe of brain, 136
- Testis, 118
 - Undescended, 118
- Tethering of breast tissue, 98
- Thorax, ill-defined sites, 150
- Thymus gland, 142
- Thyroid gland, 140
- Time limits for EOD, 1
- Tissue, soft, subcutaneous and connective, 90

- Tongue, 14, 16
 - Anterior 2/3's, 16
 - Base (posterior), 14, 16
 - AJCC definition, 14, 32
 - Border, 14, 16
 - Dorsal surface, 14, 16
 - Frenulum linguae, 16
 - Invasive and noninvasive, 11
 - Junctional Zone, 16
 - Lingual, 14
 - Midline, 16
 - Posterior 1/3rd, 14
 - Root, 14
 - Tip, 16
 - Ventral surface, 16
- Tonsil (incl. tonsillar fossa and pillar), 32
- Trachea, 78
- Transverse colon, 48
- True histiocytic lymphoma, 8, 146
- Trunk
 - Skin of, 92
- Trunk, Ill-defined sites, 150
- Tubo-ovarian, 108
- Tumor size
 - Ascites
 - Status of capsule code, 3, 106
 - Centimeters, 3, 4
 - Do NOT add chips or pieces together, 3
 - Equivalences in cm
 - Balls, golf, tennis, etc., 4
 - Doughnut, 4
 - Egg, bantam, goose, etc., 4
 - Eraser on pencil, 4
 - Fist, 4
 - Fruits, 4
 - Lentil, 4
 - Marble, 4
 - Match (head), 4
 - Microscopic, 4
 - Millet, 4
 - Money, 4
 - Nuts, 4
 - Vegetables, 4
 - In situ lesions, 3
 - Inches, 4
 - Millimeters, 4
 - Priority of code '998', 3
 - SEER rules for coding
 - Encouraged, 4
 - Required, 3
 - Size of tumor, not polyp, ulcer, or cyst, 3
 - Surgical cases pretreated by radiation, 1
- Tunica vaginalis, 122
- Ulcer, code size of tumor, 3
- Undescended testis, 118
- Undifferentiated leukemia, 148

- Unknown and not applicable
 - Extension of tumor, 7
 - Lymph nodes, 7
 - Size of tumor, 7
- Unknown primary site, 150
 - Codes for, 7
 - Size not applicable, 3
- Unstaged codes, 7
- Upper esophagus, 42
- Urachus, 126
- Ureteric orifice, 126
- Ureters, 124, 125, 130
 - Invasive and noninvasive, 124, 125
- Urethra, 132
- Urethrovaginal septum, 114
- Urinary system, 130
 - (See urinary bladder, renal pelvis and ureters.), 126
 - Bladder, 124, 125, 126
 - Dome, walls, trigone, 126
 - Invasive and noninvasive, 124, 125
 - Neck, 126
- Uteri, 100
 - Cervix, 100
 - Corpus, 104
- Uterine adnexa, 108
 - Other parts of, 108
- Uterine cervix, 100
- Utero-ovarian, 108
- Uterus, 104
- Uvula, 28
 - AJCC definition, 28, 32

- Vagina, 110
- Vallecula epiglottica, 32
- Ventricle of brain, 136
- Vermilion border, 12
- Vertebral column, 88
- Vesicocervical tissue, 114
- Vesicovaginal septum, 114
- Vestibule of mouth, 24
- Vocal cords, 76
- Vulva, 112
 - Skin of, 112
 - Kaposi's sarcoma, 112
 - Malignant melanoma, 94, 112
 - Mycosis fungoides, 112
 - Sezary's disease, 112

- Waldenstrom's macroglobulinemia, 148
- Waldeyer's ring, 38
- Widespread, 3

- X-ray no mention of nodes, 80

